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INTRODUCTION 
Neonatal hyperbilirubinemia is one of the common morbidity in the newborn 
babies. Most of the babies develop hyperbilirubinemia in early neonatal period. 
Approximately 60% of healthy term infants and 80% of premature infants develop 
clinically visible jaundice in the first week of life.In the majority of cases, jaundice is 
mild and transient. It occurs due to immaturity of the liver's excretory pathway for 
bilirubin, when the bilirubin production is more in initial days of life. Hence, most of the 
babies do not require treatment for neonatal jaundice. Some babies may show significant 
rise in serum bilirubin and require treatment to avoid serious brain injury. This occurs in 
the early neonatal days which may prolong the duration of hospital stay following the 
delivery of the baby.  
High serum bilirubin may cause acute bilirubin encephalopathy, a most dreaded 
complication of neonatal jaundice(1).Acute bilirubin encephalopathy (ABE) may evolve 
into kernicterus (chronic bilirubin encephalopathy), which is characterized by movement 
disorders like dystonia and/or choreoathetosis, hearing loss and oculomotor palsy. 
Total serum bilirubin is the measure of albumin-bound bilirubin in the serum. The 
small circulating fraction of bilirubin, not bound to albumin or other serum proteins is 
called unbound or “free” bilirubin. Free bilirubin is the one which crosses the blood brain 
barrier and act as a vehicle for the bilirubin induced neurological insult.Bilirubin-induced 
neurotoxicity depends on the interaction between the level and duration of “free” 
bilirubin exposure of the brain. The laboratory measurement of circulating free bilirubin 
2 
is not unavailable. Hence we must rely on the total serum bilirubin and the 
bilirubin/albumin (B/A) ratio to assess the risk for acute bilirubin encephalopathy and to 
decide on starting treatment. 
The key measures to prevent bilirubin encephalopathy in term and late-preterm 
neonates includes hyperbilirubinemia risk assessment, appropriate and timely birth-
hospitalization follow-up, and timely and effective treatment of marked 
hyperbilirubinemia with phototherapy and/or exchange transfusion. 
Phototherapy and exchange transfusion are the main modalities of treatment for 
neonatal hyperbilirubinemia. Current AAP phototherapy(2), and exchange transfusion 
treatment thresholds for infants greater than or equal to 35 weeks' gestation are shown in 
Figs. respectively. Phototherapy remains the most widely used modality of treatment for 
neonatal jaundice. Phototherapy is effective in reducing the serum bilirubin level in most 
of the newborn babies. Some babies with severe hemolysis, may show increasing serum 
bilirubin while on phototherapy and end up requiring exchange transfusion to prevent 
bilirubin encephalopathy.  
In clinical guidelines by American Academy of Pediatrics for diagnosis and 
treatment of jaundice(2), charts are available to decide when a newborn baby should be 
treated with phototherapy and exchange transfusion. Depends on the gestational age of 
the newborn and the associated risk factors, charts were referred and treatment options 
were decided. The guideline does not recommend when the phototherapy can be stopped. 
For infants readmitted for phototherapy after discharge from birth hospitalization, it was 
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recommended to stop phototherapy when total serum bilirubin drops below 13-14mg/dl. 
This recommendation cannot be applied to younger neonates, for whom phototherapy 
may need to started at total serum bilirubin level<13 mg/dl. 
Rebound hyperbilirubinemia can occur afterstopping phototherapy. It is due to 
continued underlying alteration in bilirubin metabolism which results in resurgence of 
serum bilirubin level. The rise in serum bilirubin level may sometimes necessitates 
readmission for treatment with either phototherapy or exchange transfusion to prevent 
neurological damage by the bilirubin.Hence it is necessary to find out the level at which 
phototherapy can be stopped without increasing the chance of rebound 
hyperbilirubinemia. 
The United Kingdom‟s National Institute for Health and Care Excellence 
guidelines(3) recommends stopping phototherapy  at serum bilirubin level of >3mg/dl 
below the treatment threshold. 
In a pilot study conducted by Barak et a(4)l, they compared the outcome of two 
group of jaundiced but otherwise healthy newborn randomized to one of the two targets 
of bilirubin concentration for discontinuation of phototherapy. They found no significant 
difference in the occurrence of rebound when phototherapy was discontinued at a TSB of 
≥1 mg/dl versus ≥3mg/dl below the AAP phototherapy threshold[5 out of 25 versus 5 out 
of 27 respectively, p=0.58], but the trial was a pilot study included only 52 neonates. 
They recommend further study with larger sample size. 
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We proposed to conduct a study with larger sample size to find the serum bilirubin 
level at which the phototherapy can be stopped.  
RESEARCH QUESTION: 
 In newborns of ≥35weeks gestational age with neonatal hyperbilirubinemia treated 
as per AAP guidelines, does discontinuing phototherapy at serum bilirubin level  1.0-
2.9mg/dl and ≥3mg/dl below the treatment threshold cause difference in the occurrence 
of significant rebound hyperbilirubinemia? 
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AIM AND OBJECTIVES 
AIM: 
To compare the occurrence of significant rebound hyperbilirubinemia between 
two group of jaundiced new born for whom phototherapy was stopped at serum bilirubin 
level 1.0-2.9 mg/dl and ≥3 mg/dl below the treatment threshold as per AAP guidelines. 
OBJECTIVES: 
Primary objective is to find out the number of babies who develop significant rebound 
hyperbilirubinemia following discontinuation of phototherapy at SBR level of 1.0-2.9 
mg/dl and ≥3mg/dl below the treatment cut off in AAP chart. 
Secondary objectives are i) to compare the total duration of phototherapy between two 
groups and ii) to compare the durationof hospital stay between two group. 
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REVIEW OF LITERATURE 
Neonatal Hyperbilirubinemia 
 Neonatal hyperbilirubinemia reﬂects the developmental changes in production, 
metabolism, and excretion of bilirubin. It is characterized by (1) an increased bilirubin 
load on immature hepatocytes and (2) decreased hepatic clearance of bilirubin. The 
increased hepatic bilirubin load is due to overproductionof bilirubin which in turn occurs 
due to large red cell mass, reduced red cell life span, and in some newborns, hemolytic 
conditions may accelerate red cell turnover. Decreased bilirubin clearance in newborns 
results from reduced hepatic bilirubin uptake and conjugation. In addition, an increased 
reabsorption of bilirubin from the intestines, enterohepatic circulation reduces the 
bilirubin excretion and increases the bilirubin load on the immature liver.  
In newborns, bilirubin has the propensity for deposition in skin and mucus 
membranes producing yellowish discoloration. It may also deposits in the brain and 
producing acute and chronic bilirubin encephalopathy. A thorough knowledge of the 
bilirubin metabolism is essential to understand the management principles and the 
potential complications.  
Bilirubin Metabolism 
Bilirubin is produced as an end product of two stage heme catabolism in the 
reticuloendothelial system. Heme is the oxygen carrying component present in the 
hemoglobin. Destruction of the red blood cells results in the release of heme from 
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haemoglobin. In the first step, heme is converted to biliverdinIXa and this rate limiting 
step is catalysed by heme oxygenase-1.This result in the release of free iron and carbon 
monoxide in equimolor amounts. Iron is reutilized in the hemoglobin synthesis and the 
carbon monoxide is excreted through lungs. Biliverdin is blue green, water soluble and 
nontoxic product of heme.Biliverdin is readily excreted by the liver and kidneys.  In 
mammals, biliverdinreductase converts the biliverdin to bilirubin IXa. Bilirubin IXa is 
the only toxic isomer of bilirubin. Bilirubin is virtually water insoluble at physiological 
pH and hence it can cross all biological membranes including blood brain barrier. 1 gram 
of hemoglobin, on degradation produces 34mg of bilirubin. Bilirubin must be conjugated 
by hepatic enzyme, uridinediphosphoglucuronateglucuronosyltransferase before getting 
excreted in bile.  
The carbon monoxide(CO) produced as the result of heme degradation binds to 
carboxy haemoglobin and excreted by lung. Quantitative estimation of the carbon 
monoxide excretion offers reasonable assessment of the heme degradation and bilirubin 
production in infants without any lung disease.4 
Bilirubin Production 
 Bilirubin is derived from the heme, which is released from the destruction of 
RBCs. Carbon monoxide excretion demonstrated that the bilirubin production is 
increased two to three times than the adult in day one of life. Bilirubin production is 
estimated to be 8 to 10mg/kg of body weight per day. This increased bilirubin production 
rapidly decreases over next two days. Factors which explain this increased production of 
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Bilirubin in early post natal days include 1)reduced life span of RBCs, 70 to 90 days 
compared to 120 days in adult, 2) very large pool of hematopoietic tissue, which stops 
functioning after birth, 3) increased turnover of cytochromes and 4) increased bilirubin 
absorption from the intestines, enterohepatic circulation.   
 
Figure 1: Bilirubin synthesis, transport and excretion 
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Bilirubin Transport 
 Unconjugated bilirubin is insoluble in water at pH 7.4. In plasma it is readily 
bound to albumin. On average, about 7 to 8 mg/dl of unconjugated bilirubin bound to 
each gram of albumin. Newborns have reduced plasma binding capacity than adults. 
Reduced binding can be because of reduced serum albumin concentration reduced 
binding capacities. The unbound bilirubin fraction is believed to be more sensitive 
predictor of bilirubin induced neurological dysfunction. But currently, there is no reliable 
method to measure the unbound bilirubin fraction. 
 Bilirubin exists in four different forms in circulation. It includes, 1) unconjugated 
bilirubin reversibly bound to albumin, 2) free bilirubin, unconjugated bilirubin not bound 
to albumin, 3) conjugated bilirubin released from liver into circulation, to be excreted by 
renal or biliary system, 4) conjugated bilirubin covalently bound to albumin. 
Unconjugated bilirubin may increase in newborn with excessive hemolysis or reduced 
bilirubin glucuronidation. Conjugated bilirubin will increase in cholestatic conditions. 
Bilirubin can be increased in newborns with prolonged conjugated hyperbilirubinemia 
due to liver disorders.  
Hepatic Uptake 
 Bilirubin dissociates from albumin before entering the hepatocytes. Bilirubin 
uptake by the liver is partly by carrier mediated diffusion and partly by organic anion 
transporter proteins. In the hepatocyte cytoplasm unconjugated bilirubin bound to 
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ligandin. Ligandin are the major intracellular transport proteins, they binds to bilirubin 
and keeps the toxic unbound fraction of bilirubin low. Z protein , a hepatocyte carrier 
protein, binds to bilirubin with a lower affinity. The equilibrium between the rate of 
bilirubin released into the circulation and its elimination determines the total serum 
bilirubin concentration at any specific time.  
The reduced capacity of hepatic uptake of unconjugated bilirubin has been thought 
to be an important factor for physiological jaundice. In newborns, the reduced bilirubin 
uptake is not considered as important as the immature bilirubin conjugation in the 
development of unconjugated hyperbilirubinemia during first three to four days of life. 
Bilirubin uptake deficiency may contribute to hyperbilirubinemia in the second week of 
life when the bilirubin conjugation increases and reaches adult level.  
Bilirubin Conjugation 
 As unconjugated bilirubin is water insoluble, it must be converted into a more 
polar, water soluble substance before being excreted into the bile. The conjugation is a 
two step process in which bilirubin is conjugated with two molecules of glucuronic acid. 
In the hepatocytes, bilirubin is transported to the smooth endoplasmic reticulum and gets 
conjugated. Conjugation of bilirubin is catalysed by the enzyme uridine diphosphate-
glucuronosyl transferase (UDPGT-1). The UDPGT-1 enzyme first catalyzes the transfer 
of one glucuronic acid molecule to form bilirubin monoglucuronide. A reduction of the 
enzyme activity to less than 1 % may result in unconjugated hyperbilirubinemia. 
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Bilirubin monoglucuronide is water soluble and it can be excreted into bile as a 
diglucuronide. The next step is the conjugation of a second glucuronide molecule to a 
monoglucuronide. This step is also catalysed by the same UGT1A1 enzyme, which is 
present in the endoplasmic reticulum. UDP-glucuronide glucuronosyl transferase 
(transglucuronidase) is another enzyme which may also play a role in the second step. 
This enzyme catalyses the transfer of one molecule of glucuronic acid from bilirubin 
monoglucuronide to bilirubin monoglucuronide. This results in the formation of bilirubin 
diglucuronide. Bilirubin diglucuronide is excreted in the bile and the unconjugated 
bilirubin released in this step will enter the endoplasmic reticulum for further 
conjugation.  
The water-soluble form of bilirubin is readily excreted in the gastrointestinal tract. 
Water solubility of the conjugated bilirubin also decreases the amount of bilirubin 
reabsorbed from the bowel. In normal adult, glucuronide conjugation helps in the 
disposal of around 90% of total bilirubin. The remaining bilirubin  is made water-soluble 
substances by conjugation with other substances like glucose, xylose, sulfates, and 
taurine. These nonglucuronide conjugates account for less than 10% of the total bilirubin 
conjugates excreted in the bile.A number of studies have demonstrated the presence of 
deficiencies of  hepatic UGT activity in newborns. Studies on rhesus monkeys and rats 
showed that the hepatic bilirubin conjugating capacity isextremely low during the first 
few days of life. The conjugating capacity of the liver increases to the adult level by the 
fourthday of life, with 75% of all conjugated bilirubin is glucuronide conjugates. In 
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newborns, the bilirubin monoglucuronideis the predominant form of conjugated 
bilirubin.UGT activity in term neonates is about 1% of that of adult level. The levels are 
much lower in premature neonates.UGT activity increases steadily until 3 months of age 
and attain the adult level.  
Excretion Of Bilirubin 
Excretion of the water-soluble conjugated bilirubin is an energy-dependent 
process. The conjugated bilirubin is incorporated into mixed micelles along with bile 
acids, phospholipids, and cholesterol. The bilirubin is then excreted against a 
concentration gradient.Bilirubin concentration of the bile is about 100-fold that of the 
hepatocyte cytoplasm. In newborn babies, in conditions like haemolytic disease of the 
newborn, a large bilirubin pool is to be eliminated. When the bilirubin load exceeds the 
excretory capacity, the efﬂux of conjugated bilirubin into the serum occurs. In the 
presence of hepatocyte injury and biliary obstruction, hepatic excretory step is more 
severely restricted and result in efﬂux of conjugated bilirubin into the serum. This results 
in conjugated hyperbilirubinemia. 
Enterohepatic Absorption Of Bilirubin 
Conjugated bilirubin cannot be absorbed from the intestine. However, mono- and 
diglucuronide of bilirubin are very unstable and are readily hydrolysed to unconjugated 
bilirubin. This unconjugated bilirubin can now be readily absorbed across the intestinal 
mucosa. This is termed as the enterohepatic circulation of bilirubin. This contributes to 
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the circulating unconjugated bilirubin pool and again presented for conjugation in the 
liver. Enteric mucosal enzyme β-glucuronidase, is present in both term and premature 
neonates in high concentrations. Studies indicate that about 25 percent of bilirubin 
excreted into the intestines were reabsorbed after getting converted into unconjugated 
bilirubin. 10 percent of bilirubin excreted in the bile is unchanged and excreted in stool. 
Remaining bilirubin is converted into urobilinoids and excreted in the stool. The 
unconjugated bilirubin present in the intestines of the neonates are high when compared 
to adults, this results in the increased enterohepatic circulation. This excess unconjugated 
bilirubin is the result of increased bilirubin production and the increased bilirubin content 
of the meconium. Also neonates does not have the intestinal bacterial flora to convert the 
bilirubin to urobilinogen, this results in the increased bilirubin available in the intestine to 
get absorbed. β glucuronidase activity of the intestinal mucosal cells also high in the 
neonates and causes increased hydrolysis of the conjugated bilirubin.  
Physiologic Bilirubinemia 
The normal increase in serum bilirubin occurs in neonates that should not be 
called as hyperbilirubinemia. The correct term would be physiologic bilirubinemia. Fig. 
shows the natural increase in serum total bilirubin during the first week of life. The peak 
of the bilirubin level occurs at about day 5 of life.  
During the last weeks of gestation, the destruction of RBCs, which are formed during 
the earlier gestation, results in a 150% increase in the production of bilirubin per unit of 
body weight. The UGT activity of human fetus is extremely low, around 0.1% of adult 
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activity, before 30 weeks of gestation. The UGT activity gradually increases to reach 
about 1% at term. This reduced UGT activity along with the increased production of 
bilirubin, increased enterohepatic circulation and reduced hepatic uptake results in the 
physiologic bilirubinemia in neonates. In fetus the hyperbilirubinemia will not occur as 
the unconjugated bilirubin which is produced will be cleared by the placenta. Even in 
severe hemolytic condition like isoimmunisation the jaundice is usually mild and only 
anemia is very apparent. After birth, when the baby is separated from the placenta, 
bilirubin starts to increase. The increase in the serum bilirubin is excessive in case of 
hemolytic diseases. However the placenta is impermeable to conjugated bilirubin, hence 
if jaundice is noted soon of the birth conjugated bilirubinemia should be suspected. Also 
in fetus, conjugation occurs in liver and excreted into intestines. In meconium, β 
glucuronidase activity is found which is responsible for the conversion of conjugated 
bilirubin to unconjugated bilirubin and get reabsorbed into the circulation. The process 
may be protective from severe hyperbilirubinemia due to hemolysis during intrauterine 
life. 
In severe hemolytic disease of the fetus, the bilirubin concentration of the amniotic 
fluid increases. The bilirubin may increase after direct transfer from the placenta or the 
cord blood vessels. Amniotic fluid bilirubin concentration is considered as a marker of 
the fetal anemia.  
 In term neonates, the total bilirubin increases gradually and attains the peak 
concentration at 72 to 120 hours. There was a significant racial difference in the duration 
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of the peak bilirubin concentration. White population usually will have an earlier peak 
than the Asian population. Prevalence of breastfeeding also significantly affect the peak 
bilirubin concentration with breastfeeding babies will have a higher peak than the 
formula feeding counterparts. Clinical examination will reveal icterus when the total 
serum bilirubin exceeds 5 to 6mg/dl. As the serum bilirubin level increases, the clinical 
icterus progresses in a cephalo-caudal direction. Hence at low total serum bilirubin, 
icterus is appreciable over the head and the sclera. When the bilirubin level increases the 
icterus gradually progress to abdomen and extremities.  Clinical examination is very 
much subjective and depends on the experience of the observer. Nowadays, noninvasive 
transcutaneous bilirubinometer is available to measure the skin color objectively. The 
reliability of the transcutaneous bilirubin measurement is better than the visual 
examination.   
In preterm neonates, the physiologic jaundice is more severe than the term 
counterparts. These babies will have a peak bilirubin concentration at about fifth day of 
life. This delayed peak is probably due to the delayed maturation of UGT activity in 
preterm neonates. Although the maturation of the hepatic UGT activity is delayed in 
preterm babies, the maturation is faster when compared to the in utero maturation.  
Pathologic Unconjugated Hyperbilirubinemia 
Increased serum concentration of the unconjugated bilirubin is of concern because 
of the risk of bilirubin encephalopathy. Although some reports are available to suggest 
that the conjugated hyperbilirubinemia also associated with the increased risk of bilirubin 
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encephalopathy. The mechanism by which, the conjugated bilirubin resulting in 
encephalopathy is not clear. Most of the studies which are available on the kernicterus 
relate the total bilirubin concentration to the cause of kernicterus. Also in these studies 
the concentration of conjugated bilirubin comprises a small fraction.  
The total bilirubin concentration at any point time is determined by the balance 
between multiple factors. The factors influencing the total serum bilirubin level includes 
production, conjugation and excretion of the bilirubin. Significant changes also occur in 
this complex system during the first week of life. It includes increased heme catabolism 
and the increasing hepatic bilirubin conjugating capacity, as it gradually matures. The net 
result of this physiological process is that the concentration of total bilirubin gradually 
increases till day 5 and then decreases. Some of the pathological condition gets 
superimposed on this physiological process and results in the exaggerated or prolonged 
neonatal hyperbilirubinemia. These conditions may affect any step of bilirubin 
metabolism like bilirubin production, conjugation or excretion.  
Causes OfUnconjugated Hyperbilirubinemia 
Disorders Of Bilirubin Production 
The most common causes of unconjugated hyperbilirubinemia in neonatal period 
include isoimmune haemolytic disease and G6PD deficiency.  
Neonates with hyperbilirubinemia due to acute hemolysis appear to have increased 
risk of bilirubin encephalopathy than the neonates without hemolysis. Watchko et al(5),in 
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their report stated that the hyperbilirubinemia without hemolysis is less dangerous than 
those with hemolysis in causing kernicterus. In another study authors found that the 
males with hyperbilirubinemia for more than five days and a positive Coombs test had 
significantly lower IQ scores than the mean for the population. Kuzniewicz et al(6), 
found that in children with a positive Coombs test, a total serum bilirubin level more than 
25mg/ dl was significantly associated with low IQ scores. Another study(7) reported that 
the threshold total bilirubin to identify babies with encephalopathy was lower when 
associated with hemolysis. A neonate with Rh isoimmunisation and a serum bilirubin 
concentration of 20-24mg/dl have an increased risk of bilirubin encephalopathy than a 
healthy neonate without hemolysis at a same bilirubin concentration.  
Table 1: Hemolytic causes of Unconjugated Hyperbilirubinemia 
Isoimmunization 
 Rh incompatibility 
 ABO incompatibility 
 Other blood group incompatibilities 
Erythrocyte Biochemical Defects 
 Glucose-6-phosphate dehydrogenase deficiency 
 Pyruvate kinase deficiency 
 Hexokinase deficiency 
Structural Abnormalities Of Erythrocytes 
 Hereditary spherocytosis 
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 Hereditary Elliptocytosis 
 Infantile pyknocytosis 
Infection 
 Bacterial 
 Viral 
Blood Sequestration 
 Cephalhematoma 
 Subdural hematoma 
 Hemangioma 
 
American Academy of Paediatrics recommends starting phototherapy or exchange 
transfusion at a lower total serum bilirubin level in a neonate with haemolytic disease 
when compared with a healthy neonate (11). This does not mean that healthy neonates 
are immune to bilirubin encephalopathy. A study be Maisels et al(8) reported the 
occurrence of kernicterus in neonates without hemolysis.  
Hemolytic disorders of newborn are broadly divided into immune and nonimmune 
hemolysis.  
Isoimmunization 
The hallmark of isoimmune haemolytic disorder is the positive Coombs test. This 
indicate that the maternal antibody get crossed the placenta and detectable in the fetus.  
19 
Rh Isoimmune Haemolytic Disease 
In the past, it was the most common cause of severe hyperbilirubinemia and 
bilirubin encephalopathy. After the increased usage of Anti D immunoglobulin and 
improved monitoring of fetus, the occurrence of severe haemolytic disease with Rh 
incompatibility is low. Recent studies showed that the blood group of the fetus can be 
identified in the antenatal period itself by PCR from fetal cell obtained from maternal 
blood samples(9) or amniocentesis(10). The degree of anaemia in fetus and the need for 
antenatal transfusion can be determined by measuring the middle cerebral artery peak 
systolic velocity.  
 Rh   blood group  antigen   are highly    antigenic    and cause    severe   
isoimmunisation,  that   lead to    fetal   hydrops.Even 0.1ml  of  fetomaternal    
hemorrhage   can   produce   marked   sensitization    by D antigen.  Rh  disease  can 
cause intrauterine    hemolysis and it continues  in the neonatal   period. If left  untreated   
severe   anemia and hydrops can occur. After birth, severe   hyperbilirubinemia   and   
kernicterus   can occur.  
 The isoimmunisation starts   when the  Rh  negative   mother get exposed to D 
antigen during trans placental fetomaternal    transfusion of fetal  RBC‟s.   After   
exposure to D Antigen, maternalimmune  system   produce  anti –D  immunoglobulin G.    
These IgG   antibodies crosses the placenta  and  attacks  the fetal   RBC‟s.Antigen 
antibody  reaction  occurs  and  leads  to hemolysis  and   anemia. This immune   
response   is  more   severe  in successive   pregnancies.Anemia  in fetus   leads    to 
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appearance   of  immature   RBCs   in  circulation.  Hydrops   is characterized   by 
generalized edema, pleural  & pericardial  effusion. This    effusion   may be  due to  
combined   factors  like hypoproteinemia, tissue  hypoxia  and   capillary    leak. Anemia   
will further   complicate    the   hydrops   by   producing   congestive  cardiac   failure   
and  venous   congestion. Increased  COHb   levels   in the    fetal   blood     obtained by  
cordocentesis   can   confirm  the  presence  of  inutero   RBC  destruction. In   utero   
hemolysis  can  manifests   as fetal  anemia.Even   with   severe hemolysis,  the serum    
total   bilirubin  concentration  is usually    below    5mg/dl, as it was   cleared by the    
placenta.  Jaundice   may start  to  appear   after   delivery. In the  initial  stage, the  
unconjugated bilirubin   contribute  to the  total   bilirubin,  later    when the bilirubin    
load is  high the hepatic system   can be    saturated   and the   conjugated   bilirubin   
starts  appearing  in  the serum. This  leads  to the  increasing  conjugated  fraction  of 
bilirubin  over time in  Rh  isoimmunisation.   Other reasons   that  may  contribute   to  
conjugate   bilirubin  rise are the  rapid maturity   of the   hepatic  conjugating   function  
when compared   to the   excretory  function.  
 
ABO   Incompatibility    
 After   the use   of immune prophylaxis, the incidence of Rh isoimmunisation   has 
decreased and   ABO incompatibility  is common   nowadays.It is  the most    common   
cause of   hemolytic   disease of newborn. Immune hemolysis due to ABO   
incompatibility  is  usually   mild and   rarely    cause   severe   hemolysis    with  
hyperbilirubinemia.In recent  studies  from  various   countries  on the  bilirubin   
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encephalopathy,   infants with  ABO  incompatibility    comprises   of 19 to 55% 
(11)(12)(13)(14). 
 ABO   heterospecificityis  the   situation  when   the blood   group  of the baby is 
either   A (or) B   and   mother with  blood    group  „O‟   this  combination  can occur   in 
about   12%  of the   pregnancies. These women with   blood  group  O can  have    raised  
titersof anti A (or)  Anti B antibodies  that  they  may   naturally  occurred  even  before  
their  first   pregnancy.In person with  O  blood   group  the   anti A  and Anti B  
antibodies.  
These babies with isoimmunisation have a risk of developing severe 
hyperbilirubinemia after birth. In babies with blood group A or B and mother had blood 
group B, around 30 percent of babies will have a positive Coombs test. End tidal carbon 
monoxide, a measure of heme catabolism showed an increased excretion of carbon 
monoxide in babies with isoimmunisation. It is also important to note that not all babies 
with positive Coombs test develop severe hyperbilirubinemia requiring phototherapy. 
Although the disease is mild in most babies, some babies will develop severe 
hyperbilirubinemia requiring intensive treatment with IVIG or exchange transfusion. 
Also babies with negative Coombs test can develop severe hyperbilirubinemia. Absence 
of disease in the Coombs positive babies can be explained by the presence of reduced A 
and B antigenic sites on RBCs in neonatal period. Antibodies may also bind to the 
antigenic sites present in the other tissues causing less severe haemolytic disease. Hence, 
the positive coombs test alone cannot be considered for defining a baby as having 
haemolytic disease. Criteria which can support to define hemolysis in a baby with ABO 
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incompatibility include Indirect hyperbilirubinemia on day 1, baby with a or B blood 
group and mother having O group, spherocytosis on the smear, elevated  reticulocyte 
count  and increased end tidal CO.  All babies born to mother with O blood group should 
be carefully followed and investigated when required.  
Other antigens which are present in the RBCs and cause hemolysis in newborn 
include anti-c, anti- Kell and anti- E anti. Alloimmunization due to these antibodies can 
cause severe hemolysis during intra uterine period. Anti Kell isoimmunisation can 
produce fetal anaemia due to suppression of erythropoiesis in addition to hemolysis.  
Nonimmune Hemolysis 
 The cause for nonimmune hemolysis in newborn includes erythrocyte enzymatic 
defects like G6PD deficiency and Pyruvate kinase deficiency, erythrocyte structural 
defects like HereditarySpherocytosis and Hereditary Elliptocytosis. Other condition 
which can result in hemolysis includes infection and sequestration of blood within the 
body cavities.  
Disorders of Bilirubin Conjugation 
 It includes Crigler-Najjar syndrome type 1and 2, which is characterised by 
complete absence or reduced activity of the hepatic UGT activity.  Type 1 is more severe 
and develops by around day 3 and progress during the first month of life. Type 2 is a less 
severe and often benign disease.  
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Pyloric stenosis can be associated with reduced UGT activity and result in 
unconjugated hyperbilirubinemia. Usually post-surgery when the obstruction is relieved 
the serum bilirubin level decrease gradually and reach the normal level in less than 3 
days.  
Hypothyroidism is also associated with unconjugated hyperbilirubinemia due to 
reduced UGT activity and reduced hepatic uptake of bilirubin. This leads to prolonged 
hyperbilirubinemia. Hence thyroid function test is suggested for infants with 
hyperbilirubinemia.  
Disorders of Enterohepatic Circulation 
It includes two types of jaundice associated with breastfeeding, one is 
breastfeeding failure jaundice and the other breast milk jaundice.  
Breast failure jaundice occurs in the exclusively breastfed babies in the first weeks 
of life. Mothers who find difficulty in establishing good breastfeeding techniques were at 
risk of ineffective breastfeeding. This results in the poor oral intake by the baby and leads 
to stasis of the intestinal contents. This result in the increased enterohepatic circulation of 
bilirubin and more bilirubin will be handled by the immature liver. This series of events 
result finally in exaggerated unconjugated hyperbilirubinemia. Breastfeeding failure 
jaundice can be prevented by ensuring frequent breastfeeding and proper lactation 
counselling.  
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Breast milk jaundice occurs later part of first week and may continue till third 
week of life. Usually the peak serum bilirubin ranges from 5 to 10 mg/dl at two weeks of 
life. This peak is followed by a gradual decrease in the serum bilirubin level over months. 
Some babies may get severely affected and have a maximum serum bilirubin level of 20 
to 30 mg/dl. In contrast to babies with breastfeeding failure babies these babies feed well 
and grow well. Studies shown that the presence of non-esterified long chain fatty acids in 
the milk  as a cause for breast milk jaundice. Usually these neonates were well appearing 
and no treatment is needed unless the serum bilirubin rises to a dangerous level. In those 
circumstances, interruption of breastfeeding and supplemented with formula feeding, for 
about 1 to 3 days well result in fall of serum bilirubin level to 50% of the previous level. 
Before interrupting breastfeeding other causes of hyperbilirubinemia like hemolysis, 
hypothyroidism, should be excluded.  
Sequelae of Unconjugated Hyperbilirubinemia 
In children with kernicterus, intellect may be spared sometimes, but the physical 
handicaps may be severe to lead an independent life. Also, some children with 
kernicterus might not had features of any bilirubin encephalopathy during their newborn 
period. A recent study on 25 cases of kernicterus found that 60 percent of children could 
not walk, 52 percent only able to feed themselves and 36 percent had severe intellectual 
disability. Mortality rate of kernicterus is 50 percent in term neonates. In preterm babies, 
the signs of encephalopathy may not be evident.  
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Factors which influence the bilirubin encephalopathy include increased bilirubin 
production, altered bilirubin binding capacity of albumin and altered permeability of 
blood brain barrier. It is believed that when the bilirubin binding capacity of albumin 
exceeds the limit and unbound fraction of bilirubin increases in serum, bilirubin 
encephalopathy occurs. The bilirubin binding capacity of albumin decreased in condition 
like sepsis and hypoxemia. Also the free fatty acids increases in sepsis and hypoxemia, 
this displaces the bilirubin from albumin and free bilirubin level increases in the serum 
resulting in bilirubin encephalopathy. Disruption of blood brain barrier in condition like 
meningitis and hypoxemia can result increased permeability to bilirubin and neuronal 
damage. After entering brain bilirubin interferes with the functions of neuronal cell and 
can also cause damage to DNA.  
It is   well know that  unconjugated   bilirubin can   penetrate   the brain cell  and  
result  in  neuronal  damage. This is the reason why unconjugated hyperbilirubinemia is 
carefully  managed   in  infants. Although   it was   thought    that  kernicterus  have been  
extinct  from the   developed  countries, studies   shows   that the  condition  still 
continues  to occur. Acute bilirubin   encephalopathy and its sequelae, kernicterus are a 
preventable   condition. It cannot be said that single total bilirubin   concentration as a 
safe or a dangerous one. The total serum bilirubin concentration widely used to determine    
the need for treatment is a poor predicator of neuro developmental  outcome . In  a study  
by   Gamaleldin  et  al(7),  they  found   that there   was   little  correlation   between the  
admission  total bilirubin   and    occurrence  of  acute   biliary   encephalopathy. 
26 
As per   another   study (15), bilirubin neurotoxicity is   unlikely   in a   healthy   
term  infants    without  any   hemolytic   condition   with  a    total  bilirubin    
concentration of  less   than   25mg/ dl.    In  presence  of risk factor  like  hemolysis,  
prematurity  or    sepsis,    bilirubin   encephalopathy can occur   at   a lower   total   
bilirubin level. 
In  a term   infant   with  active  hemolysis,  total   bilirubin  concentration  should 
not   exceed  18-20 mg /dl.   Hyperbilirubinemia   should be considered as potentially   
dangerous   condition    as it can   cause  a   spectrum   of  neurological  dysfunction  
ranging  from mild and transient  encephalopathy to a serve   permanently   disabling  
neurological  impairment, kernicterus. It is also important    to note  that   the  bilirubin  
metabolism   is a    dynamic  process    and  any one   serum  bilirubin value  is not  
sufficient to assess  the risk  of neurological   damage  in a neonate.  Other factors   like   
gestational   age and  general   health should  also be considered in evaluation of neonate 
with hyperbilirubinemia.  
The   incidence  of kernicterus  differ   between  countries   and  range   from  0.4 
to 2 per  lakh children    in the   developed   countries.   In developing countries   and in 
areas   with less   developed   health   services, the incidence of kernicterus   is still   
higher. As the occurrence of kernicterus is rare, the incidence of extreme   
hyperbilirubinemia  (total   serum  bilirubin  >25mg/ dl)  can be   taken as a   surrogate  
for  determining  the incidence   of kernicterus. Even with good surveillance for 
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hyperbilirubinemia  during  the  hospital   stay  and following   discharge,    a zero   rate 
of   extreme  hyperbilirubinemia  is difficult   to achieve. 
 The  readmission rate  for  hyperbilirubinemia  ranges  from   0.17%  to 
3.2% .The common  cause  for  readmission for  hyperbilirubinemia  were   prematurity, 
inadequate   breastfeeding   and  early  discharge . Even  with close  surveillance   in a   
well   organized health system (16), extreme hyperbilirubinemia  occurred   in  0.14%  of  
newborn and   0.01%   had total    bilirubin   concentration    more than  30mg/dl. As per   
another   study(17)   0.12%   of newborn   with  35 weeks or more   gestational   age, had  
bilirubin  concentration above  the  AAP   cut-off  for  exchange     transfusion. 
Acute Bilirubin Encephalopathy  
It is characterized   by poor   feeding, lethargy,  hypotonia and high pitched cry in 
a neonate with severe hyperbilirubinemia. Hyperextension   of extensor muscle may 
follow later.  This    early bilirubin   induced encephalopathy may be transient  and is not   
necessary   that an infant  with acute bilirubin encephalopathy later  show   features  of 
kernicterus.   This is   suggested   by the reversal   of symptoms like lethargy   following 
an exchange   transfusion in a baby with features of acute bilirubin encephalopathy.  
Brain stem auditory evoked   response    may show changes characteristic of acute 
bilirubin   encephalopathy.   Prolonged    latencies in peak IV- V and interface  I-V  
suggestive of  brainstem  conductive   dysfunction. These   changes   usually   reverse  
following   the decline   in the  total bilirubin   concentration.   Long  term   follow up of 
children  with  abnormal   BAER    findings    during  their  neonatal  period   is not   
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available,  hence  the  significance  of  abnormal   BAER  is still    questionable.  
Abnormal   BAER suggest that the injury   occurs in the 8th cranial nerve   and the   
function  of cochlea   will be normal. Hence in  neonate   suspected  of having  bilirubin  
induced  auditory   damage, BAER  should be   performed   MRI   findings  in acute 
bilirubin encephalopathy includes focal   changes   in  medial   lobe  of hippocampus   
and  globus  pallidus. 
Kernicterus  
If Acute Bilirubin Encephalopathy (ABE)   was not   recognized  and treated   
properly   it can   progress  to  permanent  neurological   impairment.     Kernicterus   was 
the   term   used  in the   past to   described   the pathological  change  of bilirubin  
toxicity in the  brain. The areas   commonly  involved are the basal ganglia, 
hippocampus, sub thalamic   nucleus and cerebellum.   Cerebral cortex  is  relatively   
spared . Autopsy of   infant affected with  kernicterus   showed   lesion   in   intestinal   
mucosa, renal  tubular cells and   pancreatic  cells.  Several   phases   have been  
described   to denote   the   progression  from  ABE to chronic athetoid  cerebral palsy. 
Phase I is  characterized by  the presence    of poor   suck. hypotonia  and reduced   
sensorium.    Phase   2  is   marked  by fever,   hypertonia,   retrocolis   to frank   
opisthotonus posturing.   Phase  3 is  characterized   by high   pitched cry,  poor   feeding,  
visual    and hearing  disturbances  and    athetosis.   Some   neonates  may have   seizures   
during   phase 3.  The  usual    duration   for the   progression of the  disease   is  24 
hours.   Long   term   survivors  usually  will  show   classical   sign of   kernicterus . It 
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includes   tetrad   of   choreo -   athetoid cerebral palsy,  upward   gaze   palsy,   
sensorineural  hearing   defect   and dental  dysplasia   during    childhood.  
The intellectual functions of the child will be spared mostly. Mental retardation 
though seen is not a common morbidity. These children although have normal 
intelligence commonly suffer from severe physical handicaps. Children who never had 
features of bilirubin encephalopathy in neonatal period can show features of bilirubin 
induced neurological damage in later age. The theory postulated for this phenomenon is 
that children might suffer from subclinical encephalopathy at neonatal period and 
manifest at later age. They mostly have features of motor dysfunction or abnormal 
cognitive function. 
A recent report from California illustrates the clinical picture of the children who 
never had encephalopathy pictures at neonatal period. 60% of them fail to walk at a mean 
age of around 8 years. Severe mental retardation was found in 36% of those children and 
32% had no features of intellectual disability.  Epilepsy and visual or auditory 
impairment were also commonly seen in those children. 
Preterm neonates will not show typical clinical picture of bilirubin 
encephalopathy, and they usually appear sick. In preterm neonates bilirubin can enter the 
brain at lower levels of serum bilirubin level than in term neonates. Also the bilirubin 
staining of central nervoussystem structures may not indicate kernicterus in preterm 
infants. They may be due to differences in blood brain barrier (BBB) permeability to 
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bilirubin and bilirubin metabolism than occurs in the brain structures.  Mortality rate in 
kernicterus is about 50% of term infants and in preterm infants it may be even higher.  
 
Figure 2: Mechanisms of bilirubin induced neurotoxicity 
Bilirubin enters the brain through various mechanisms. It includes (1) bilirubin 
production that exceeds the buffering capacity of the blood, (2) changes in the bilirubin-
binding capacity of albumin, (3) increased permeability of BBB to bilirubin and (4) some 
unknown factors.  
Unconjugated bilirubin is highly lipid soluble and it primarily binds with albumin 
in plasma. It can also bind to other substances like β-globulin when the albumin-binding 
capacity is saturated. 
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It was believed that bilirubin toxicity occurs in circumstances where the albumin-
binding capacity of bilirubin is saturated. This results in increased unbound or “free” 
bilirubin concentration in blood. 
Each human albumin molecule can bind with at least two molecules of bilirubin. 
At a molar ratio of 1, one gram of human albumin binds with 8.2 mg of bilirubin. 
When the albumin concentration is 3 g/dL, the bilirubin binding capacity is about 
50mg/dl. 
The bilirubin-binding capacity of albumin will be decreased in any sick neonates. 
Also, the serum albumin concentration is often low in sick neonates when compared to 
the healthy neonates. Hence these sick term and premature neonate are at increased risk 
for neurological damage at lower serum bilirubin levels. The change in the bilirubin 
binding capacity of albumin in acidosis was not well studied.  
 Free fatty acids, which are increased in neonates with sepsis and hypoxemia, are 
capable of displacing bilirubin.  Drugs like indomethacin, and salicylates can displace 
bilirubin. Ampicillin, when injected rapidly can displace the bilirubin from albumin.   
Disruption of blood-brain barrier will results in the passage of substances that 
were normally prevented from entering the brain. Hypertonicity of intravascular fluid, 
meningitis, and hypoxia are the conditions in which the permeability of bilirubin into 
brain is increased. It was found that unconjugated fraction of bilirubin is a substrate for 
phosphorylated glycoprotein and this substance present in the  blood-brain barrier play a 
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major role in preventing the free passage of substances into the brain. P-GP is an ATP 
dependent plasma membrane transport protein. It transport various substances across the 
biologic membranes. Other factors are also identified to play a major role in regulating 
bilirubin entry into the brain.  
Kernicterus has been reported in adults with Crigler-Najjar syndrome type I, when 
serum bilirubin concentrations increased to more than 45 to 55 mg/dL. In neonates the 
kernicterus can occur in a serum bilirubin level less than seen with the adults. This 
suggests that the blood brain barrier may mature over age.  
Bilirubin may be produced within the brain in addition to reticuloendothelial 
system. The brain contain two isoforms of heme oxygenase, HO-1 and HO-2, they 
convert heme to biliverdin.  In normal circumstances, HO-1 shows little activity in the 
brain, but in response to stress this enzyme get up regulated. Majority of HO activity in 
the brain is due to the result of constitutive enzyme HO-2. Both of these enzymes, HO-1 
and HO-2 are distributed in only selected areas of the brain, many of them play roles in 
motor and auditory function.  
Biliverdin reductase that is present in the brain, catalysing the conversion of 
biliverdin to bilirubin. The bilirubin which is formed is rapidly cleared in normal 
circumstances by bilirubin oxidase; Studies suggests that this fraction of bilirubin pool 
can cause kernicterus. These enzymes are developmentally regulated and their functions 
were inﬂuenced by many of the disease states previously mentioned. The bilirubin is 
produced and metabolized in brain and so it must be transported out of the brain. 
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Conditions causing disturbances in the bilirubin transport mechanism may cause damage 
to the developing brain. 
Once bilirubin has entered into the CNS, it can cause neuronal damage by variety 
of mechanisms. The mechanism which were studied include (1) passage through the cell 
membranes into the lipids of cellular organelles such as mitochondria, then it can 
interfere with some important steps in energy metabolism; (2) bilirubin can binding to 
specific cellular membrane, or cytoplasmic proteins, and then it inhibit their function; and 
(3) bilirubin cause damage by directly interfering with the function of DNA. The 
bilirubin induced neurotoxicity is under research and much of the mechanisms were yet 
to be identified.  
As already discussed, HO catalyzes the reaction that convert heme into biliverdin. 
This result in releasing equimolor quantity of CO. Carbon monoxide can function as a 
neurotransmitter inside the CNS and it has been to play a critical role in memory. 
However, CO can also behave as a neurotoxin and results in deleterious effects, which 
may sometimes results in neuronal necrosis. The deposition of bilirubin in the brain in 
patients with kernicterus may not be the primary insult as previously thought, but can be 
a marker of neuronal damage produced by some other mechanisms. Bilirubin has a very 
good antioxidant property and at normal levels, provides protection from oxidative 
injury.  
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Independent of the mechanism of bilirubin neurotoxicity, clinical decisions 
regarding the management of hyperbilirubinemia and the institution of therapy are based 
on the total serum bilirubin concentration. 
Diagnosis of Unconjugated Hyperbilirubinemia 
About two out of three babies born will show clinical jaundice, but the number of 
babies who develop severe jaundice will be less. The duty of paediatrician is to find 
babies who are at risk of severe jaundice.  
The AAP guidelines provide recommendation for the evaluation of jaundice in 
newborn(2). 
Total Serum Bilirubin measurement: 
 Once a baby is noted to have jaundice clinically, total serum bilirubin should be 
done. The measurement of direct fraction of bilirubin was not shown to be useful in 
earlier stages but it must be measured in babies with prolonged jaundice and in babies 
when direct hyperbilirubinemia is suspected. In most of the babies repeat serum bilirubin 
measurement is necessary to know the trajectory and also to ensure that the threshold 
level to start the treatment was not reached. Sometimes daily serum bilirubin 
measurement is necessary until the declining trend in the serum bilirubin is documented. 
In is necessary to judge a neonate clinically and suggest whether the bilirubin monitoring 
can be done as outpatient or hospitalization is needed. Hence babies should be 
categorizes as low risk or high risk depends on the chance of developing severe jaundice. 
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Babies with onset of jaundice less than 24 hours, with hepatosplenomegaly or with 
evidence of hemolysis are considered to have higher risk of developing severe 
hyperbilirubinemia.  
 
Figure 3: Bhutani’s normogram for predicting risk for severe hyperbilirubinemia 
 Bhutani et al, published an hour specific bilirubin normogram of predischarge 
total bilirubin concentration to predict the risk of developing severe hyperbilirubinemia. 
The risk of severe jaundice in a baby with a pre discharge serum bilirubin at high risk 
zone (95
th
 percentile) is 57%. The risk is 13% for high intermediate risk zone (75
th
 to 95
th
 
percentile), 2.1% for a baby with serum bilirubin in low intermediate risk zone (40
th
 to 
36 
75
th
 centile). Infant with pre discharge bilirubin fall on low risk zone (<40
th
 percentile)has 
no risk of severe jaundice. Although the risk of severe jaundice is almost nil if the pre 
discharge serum bilirubin falls on low risk zone, AAP recommends that all neonates 
should be followed up within few days after discharge. Repeat serum bilirubin should be 
plotted on the normogram to know the trajectory. If the serum bilirubin level crosses 
from a lower risk zone to a higher risk zone, it should be considered significant and 
further close follow up is needed.  
 Methods of bilirubin estimation also should be taken into consideration. High 
Performance Liquid Chromatography (HPLC) is the most accurate method for estimation 
of serum bilirubin. Other methods may under estimate the serum bilirubin level to 
varying degrees.  
 In a neonate with hyperbilirubinemiafurther evaluation should be done in 
situations like (1) cord blood bilirubin level >4mg/dl, (2) rate of bilirubin rise is more 
than 0.5mg/dl/hour over a period of 4-8 hours, (3) rate of rise more than 5md/dl/ day, (4) 
serum bilirubin level increased to more than 15mg/dl in a term neonate, (5) more than 10 
mg/dl in a preterm neonate, or (6) when the jaundice persists for more than 14 days.  
Second line investigations in a neonate with hyperbilirubinemia should be based 
on the history and physical examination. History should include the pattern of feeding 
and a detailed family history to get a clue for familial cause of hyperbilirubinemia. 
Physical examination should include a careful examination of neurological status and 
organomegaly for haemolytic cause.  
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Initial laboratory investigation should include maternal blood grouping and typing, 
direct Coombs test, haemoglobin, blood smear for RBC morphology and reticulocyte 
count. In babies with ABO incompatibility direct Coombs test should be repeated at least 
once because at initial stages it can be negative even with evidence of hemolysis. 
End tidal Carbon Monoxide (ETCO) will be elevated in haemolytic conditions, but 
it is not readily available. G6PD assay can be ordered in selected babies with unexplained 
jaundice with evidence of hemolysis. Other investigations like enzyme studies and 
genetic testing can be reserved for selected babies with chronic hyperbilirubinemia. In 
babies with conjugated hyperbilirubinemia, liver function test should be included in 
investigation package.  
Factors which should be considered while assessing a neonate for risk of 
developing bilirubin encephalopathy should include total serum bilirubin, gestational age 
and evidence of hemolysis(2). AAP guidelines recommends provide recommendations 
for initiating treatment for neonates with >35 weeks of gestational age.   
The determination of unbound serum bilirubin concentration can be a more 
definitive marker to assess the risk of encephalopathy in a child. Studies(18)(19), shown 
that the unbound bilirubin concentration better correlate with the bilirubin 
encephalopathy than the total serum bilirubin. 
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Transcutaneous Bilirubinometry 
This method provides a more objective measure of skin colour from which serum 
bilirubin can be estimated. The device uses reflectance photometry to assess the skin 
colour. Studies have shown that in serum bilirubin level <15mg/dl, the transcutaneous 
bilirubinometry will provide values within a range of 2 to 3 mg/dl. This can be taken as a 
screening method for predischarge bilirubin measurement, but not for initiating treatment. 
Also in serum bilirubin level >15mg/dl, this method is not adequately studied.  
End Tidal Carbon Monoxide 
 Heme is broken down into equimolor concentrations of bilirubin and carbon 
monoxide (CO). Hence the concentration of CO in the end tidal breath can be used to 
identify the rate of heme degradation. This ETCOcan be used to identifythe rate of heme 
degradation. This ETCO can accurately measure the heme catabolism. Hence, ETCO can 
be used to identify a neonate with increased bilirubin production. 
Bilirubin to Albumin Molar Ratio (BAMR) 
The unconjugated bilirubin level can be indirectly measured by the bilirubin to 
albumin ratio. The bilirubin binding capacity of the albumin can vary significantly in sick 
newborns. BAMR can be used as a determinant to decide on the need for exchange 
transfusion in a baby. Also, AAP guideline (2), mentioned that serum albumin <3.0 g/dl 
is a risk factor for bilirubin encephalopathy.  
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Treatment of Unconjugated hyperbilirubinemia 
 Phototherapy remains as the mainstay of treatment for neonatal 
hyperbilirubinemia. It is well known for decades that phototherapy can reduce the total 
serum bilirubin and also prevent the rise of serum bilirubin in haemolytic conditions. 
Other treatments which are available includes exchange transfusion, IVIG and 
phenobarbitone.  
Phototherapy 
 Phototherapy is most commonly used treatment modality for neonatal 
hyperbilirubinemia. It decreases the serum bilirubin level and also it prevents the rise of 
serum bilirubin. It is effective irrespective of the cause of unconjugated 
hyperbilirubinemia. As there was no long term side effects reported so far, it is 
considered as safe for short term treatment. It also reduces the number of exchange 
transfusions in severe hyperbilirubinemia. Also neonates who were treated with 
phototherapy in addition to exchange transfusion reported to have less severe 
neurological sequelae. 
 Phototherapy can reduce the serum bilirubin be three independent mechanism. 
Photoisomerization is the most important mechanism of the three. The Z form of 
unconjugated bilirubin IXα is converted into E form. This E isomer is more soluble and 
can be excreted in bile without conjugation. Structural isomerization converts bilirubin 
into lumirubin and this also can be excreted without conjugation. The third mechanism is 
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the photooxidation, the productof photooxidation results in the production of 
monopyroles, dipyroles and biliverdin. These can be excreted in bile without further 
conjugation.  
 
Figure 4: Mechanisms of Action of Phototherapy 
 Different devices are used worldwide for delivering phototherapy and most of 
them are not standardised. Physicians should have knowledge about the factors 
influencing the efficacy of phototherapy. It includes the light source used, irradiance of 
the phototherapy unit and the body surface area exposed to phototherapy. The wave 
length of the light used is the most important variable determining the efficacy of 
phototherapy. The ideal wave length should be in between 460 and 490 nm. Studies(3) 
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have shown that phototherapy with green light is also equally effective in treatment of 
neonatal jaundice. The green light phototherapy was not widely accepted.  
Irradiance is the second important variable which determines the efficacy of 
phototherapy. Minimum irradiance needed to provide phototherapy is 6-12 μW/cm2/nm. 
Normally phototherapy therapy unit will be placed at 40 cm distance from the neonates. 
If effective phototherapy is needed the distance can be adjusted to 15- 20 cm. For 
intensive phototherapy, the irradiance can be increased to >30 μW/cm2/nm. 
Increasing the body surface area exposed is another way of increasing the efficacy 
of phototherapy. The lamps should be placed behind the Plexiglas. These Plexiglas will 
protect the infant from Ultra violet radiation that can be emitted from tha light source 
used. Minimal clothing should be allowed to increase the surface area exposed to 
phototherapy. 
AAP guidelines (2) recommend using intensive phototherapy when the serum 
bilirubin increases and approaching the threshold for exchange transfusion. Intensive 
phototherapy is defined as >30 μW/cm2/nm irradiance delivered to maximum surface 
area of the neonate.  
Blue light emitting diodes (LED) are the new methods introduced recently. They 
are effective in providing high intensity phototherapy without the disadvantage of heat 
production. These lamps also have longer life and need not be changed frequently.  
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 Intermittent phototherapy is a newer concept, bur studies with on- off cycle of 6 – 
12 hours did not shown to be effective in delivering phototherapy. The time period taken 
for the bilirubin to restore in skin for Photoisomerization occurs in less than 3 hours, 
hence intermittent phototherapy with on- off cycles less than 1 hour was found to be 
equally effective as continuous phototherapy. This intermittent phototherapy provides 
adequate time for mother infant bonding and breast feeding.  
Home phototherapy is another method that was recently studied. The advantages 
of home phototherapy include reduced cost, increased maternal bonding and parental 
satisfaction. The effectiveness of the home phototherapy was not extensively studied and 
was not recommended in neonates with higher serum bilirubin concentration or when the 
total serum bilirubin is approaching exchange transfusion threshold. 
Figure 5: AAP guidelines for phototherapy in infants with ≥ 35 weeks gestation 
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AAP guidelines(2), provide recommendation on serum bilirubin for initiation of 
phototherapy. The factors taken into consideration while referring the guidelines were the 
gestational age, the risk factors and the postnatal age. AAP guidelines did not provide 
recommendation for neonates with <35 weeks of gestational age. NICE guidelines 
provided graphs for use in treatment of premature neonates with phototherapy and 
exchange transfusion.  
 Lazar   et al(20),  in his   study    on 58  numbers  with  non   hemolytic   neonatal   
hyperbilirubinemia   ( 28  term   and    30 preterm infants )  he  tried   to find out  the 
serum    bilirubin    level  at which phototherapy could be stopped. In that study,  
phototherapy   was started  in  healthy  term   infants   when   total serum bilirubin    
reached 17mg/dl  and 14mg/ dl in preterm   infants. In  their   study phototherapy  was   
discontinued arbitrarily  at  total serum bilirubin  of   13± 0.7mg/ dl  in  full term  infant   
and  10.7± 12mg/dl in    preterm   infants . They  found  that   there   was no   significant   
rise in  serum  bilirubin  in both   term and   preterm  infants. Based on his study, they 
suggested  to stop    phototherapy  when  the  total serum bilirubin is  14mg/  dl  (or ) less 
in   full  term and  12mg/ dl  or less  in  preterm   infants with 32- 36 weeks of 
gestation.They also suggested that repeat   bilirubin     measurement   was not   necessary  
after stopping   physiotherapy .  
 Tan et al(21), recommended two consecutive bilirubin value< 11mg/dl   for 
stopping phototherapy. He also suggested daily monitoring of   serum   bilirubin for 
minimum two day to determine   maximum rebound  
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 Del Vechioet al(22), in 1991   reviewed their experience with 48 neonates over a 
period of 18 months. He found that only one infant required re- initiation of phototherapy 
out of 48 healthy neonates. The   mean serum    bilirubin  at  discontinuation of 
phototherapy   was  15.1mg/ dl   and the   average   serum   bilirubin  at rebound when  
checked   at  6-8hrs  after   stopping  was 14.9mg/dl.  
 He    supported    the view   of Yetmanet  al(23),  and Lasar et al(20),   that the  
rebound   bilirubin  measurement was not   needed  after     stopping    phototherapy   in 
healthy infants.Babies   with   hemolytic   condition   (or)   preterm    infants   were not  
included  in his   study. Rebound  bilirubin  measurement    was checked   at  6-8 hrs after   
stopping  the   phototherapy in this study.  
 In another retrospective  study by   Maiselset al(24), aimed to  determine the 
number of infants who received repeat       phototherapy,   they  included     303  term   
and near  term  infants. In the study     infants  were   divided   into   two groups   based 
on    whether  phototherapy   was started    during   birth   hospitalization or re admitted 
for phototherapy in babies   discharged previously. In the study, the decision to initiate 
and to discontinue phototherapy, and measurement of rebound bilirubin were made by 
treating physicians. 
 In group I,  13 of 158 babies (8.2%)  received  second   course   of phototherapy      
and in  group   II,   1 of  144  infants   (0.7%)  received  phototherapy. They   noted   that   
increase   in total serum    bilirubin   following   discontinuation   of phototherapy    was  
significantly   lower  in group  2.The age at  which   the    phototherapy  was started  were  
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high in   group   2 ( 4.6±1.8 days) . Hence  this fall  of the  peak  of natural course   of  
neonatal  jaundice. This   could be  the  reason for the  less  rebound  serum   bilirubin  in 
group 2 . They   suggested   for infants  during birth    hospitalization   and with  
hemolytic   disease, a   rebound  bilirubin level should be checked  after 24 hours   of 
discharge. They also suggested that rebound  bilirubin measurement was not necessary in 
infants readmitted for phototherapy   as  the rebound  increase is  less likely. The  
limitation of the   study   was that,it was  a  retrospective  study    and  there is  no   
standard   protocol   to stop  phototherapy in the babies. It  wasdone as per the discretion 
of the treating physician. 
 Al Saediet al, in 2002(25),    published   a retrospective study,   which   aimed   to 
determine  whether serum   bilirubin   rebound    occurs   within    24 hours   after 
discontinuation   of phototherapy     in term   infants . In 301 infants  with mean  
gestational   age of  39.4±14 days   and  birth   weight   3200±600gms, the serum  
bilirubin   at discontinuation   of phototherapy   was  179±47   micromole/L  and the 
rebound  serum  bilirubin  level   was 177 ±47  micromole/L . In   the study.the  follow  
up bilirubin   was measured   at   8.3±5.3 hours . The  limitation  of this  study include  
the study design,  a retrospective study    and  the  discontinuation   of phototherapy was 
done as  per the  treating  physician‟s   discretion . The   follow up serum   bilirubin 
measured  at an  earlier  age,with mean age of   8.3 hours  showed  no significant  
increase the bilirubin  level.  
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 Kaplan et al(26),  published    their   study  in  September 2005, they   did  a 
prospective  clinical   survey aimed to  determine   the incidence   of post  phototherapy    
plasma  total   bilirubin  rebound. They   did the study   on 226 term   and  near   term   
neonates  treated   with  phototherapy. He defined the significant rebound   
hyperbilirubinemia   when   the total    bilirubin  >250µmol/L. In the  study , they   tested  
the plasma   total   bilirubin   at 24 hours  after    discontinuation of phototherapy (12 -36 
hours). Of the  226    neonates,  30 developed  significant rebound  of plasmabilirubin   
and   twenty  two of  them were  treated  with repeat   phototherapy.Multiple    logistic   
regression    analysis    showed that  the  positive    direct Coombs test   and gestational   
age    <37  weeks   were the   significant risk factor  for the cause for rebound    
hyperbilirubinemia.Number  of   neonate  who developed  rebound bilirubin was more   
when the  phototherapy     was started  at age  <72 hours  than it was started>72 hrs. The   
strength    of the   study  was the    prospective   design and they   had  a  predefined    cut 
off   of  >256  micromole/L of total plasma bilirubin as the   significant   rebound   
bilirubinemia.They  mentioned  that their routine indication  for discontinuation of 
phototherapy was    205μmol/L (12mg/ dl) and they  defined   the significant   rise   as 
25%   increase  from their  discontinuation  cut off . They   measured  the plasma 
bilirubin  at 24 hours  (between 12  and 36 hrs)  after  stopping   phototherapy.  They also 
did  a subgroup analysis based whether the phototherapy was started during birth 
hospitalization or during re admission.In the second group, none  of  the   babies  showed  
significant   rebound   hyperbilirubinemia . In their   study,   out of the  30 neonate   who 
developed significant   bilirubin  rebound,    22 were  reinitiated   with   
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phototherapy.They found out that therisk  factor  for  reinitiation  of phototherapy  
included  direct Coombs test positivity, gestational age <37week and G6PD   deficiency. 
The  decision   to start   repeat   phototherapy  was at the  discrete   of the attending   
neonatologist   in the study. They  didn‟t have  protocol  to start   phototherapy  in 
rebound    jaundice.From    their study,they suggested  the neonate  with  the   risk   factor   
such  as  Coombs positive  isoimmunisation,    neonates   with    <37 weeks   gestation   
and neonate   treated   <72 hrs  are at   high    risk  of rebound   bilirubinemia . They  
suggested  to follow   these babies  for rebound   jaundice.  
 Erdeve    et   al,(27),   evaluated  rebound   bilirubin   level measured   within 
12hrs after discontinuation of phototherapy . They   included  a total   of 375  neonates,   
305 term   and 70 preterm  neonates.  In their   study the mean   total   bilirubin  level at 
starting  phototherapy was  15.41±0.38 mg/dl  and at stopping   phototherapy was 10.86  
± 0.14mg/dl. The  rebound   bilirubin   measured  at 12hrs   after stopping    phototherapy   
showed   a mean   level    of 10.84 ±0.14. He reported  that the   rebound   in serum  
bilirubin  was low  and  almost   half  (  49.1%)    of neonate   had reduction in serum 
bilirubin after stopping    phototherapy when checked for rebound hyperbilirubinemia.   
Their   study   reported   that   5.1% of neonates (19/375) needed   repeat  
phototherapy.Out of  19 neonates,  16  were term and   3 were   preterm . In their   study   
they  used    the charts   which  were   recommended   by   AAP  for the   institution   of 
phototherapy .  
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 Bansal et al(28),  in their   study  aimed  to   determine  the  incidence  of  post   
phototherapy  bilirubin rebound, they included   245  neonates. The study included   both   
term  and  preterm   neonate and they  followed  the AAP  guidelines   for starting     
phototherapy    for neonates  with    >35 weeks   gestational   age. They stopped   
phototherapy  in neonates    with  hemolytic  jaundice   when   two   consecutive  total   
serumbilirubin    levels   were less  than   14mg/dl  and in    non-  hemolytic 
conditionsthey stopped phototherapy when  the serum  bilirubin    falls  less than  
14mg/dl  for   neonates   with<35 weeks    of  gestational   age.  They   used    hours   
specific cut-off    for starting  and   stopping  phototherapy. They stopped phototherapy 
when  totalserum bilirubin  falls 2mg/dl below the level at which phototherapy  was 
started. They measured  the  rebound   bilirubin  at  24±6hrs after stopping  phototherapy. 
They  defined   significant  bilirubin    rebound as when  the post phototherapy bilirubin 
rises to a level  needing   reinitiation  of phototherapy. In these study of 245 neonates, 
post phototherapy  bilirubinwas measured  for 232  neonates.They  found   that 17 
neonates ( 7.3%)   developed   significant   rebound   jaundice and the   bilirubin  rise was   
2-3mg/dl  after   stopping  phototherapy in babies   with significant   bilirubin   rebound. 
From  the study, they     concluded  that   the risk   factors for significant  bilirubin  
rebound  were  gestational   age < 35 weeks,   birth weight  <2000gms  and  onset  of  
jaundice   < 60 hours   of age.It was  also  stated  that   after   excluding  these mentioned   
risk  factors, the incidence of significant rebound  was only  2.3%  (2/86). They included    
both   term   and preterm neonate in their study. 
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 In their  study  they stopped  phototherapy at  14mg/dl for the  neonates  with  GA 
>35 weeks    with  the  presence of  risk    factor   like  hemolysis. In  neonates,   with 
onset   of jaundice   <60 hrs  of age  with risk   factors,  the cut off of 14mg/dl could be 
high to stop phototherapy. This   could  be   the  reason why in their  study, they 
experienced   a higher  rebound  in these  neonates. 
 Berkwitt et al(29), in  his   retrospective  study aimed to evaluated   the  clinical  
utility of inpatient  rebound bilirubin level.Out of   226  neonates, rebound   bilirubin   
levels were    measured    at  61 ±2.4 hours  in 130  neonates   and rebound   bilirubin   
level were  not   measured  in 96 neonates. Theoutcome  measured  were  the length   of 
hospital stay and readmission  for   phototherapy.  They found that there was no  
significant difference in readmission   rate between   the  two groups. They also   
conclude   that  need for   phototherapy were   significantly   low when  the  phototherapy   
was continued   till the   serum  bilirubin  reaches  to   <14mg/dl .  
 A randomized trial  by  Niknafs et al(30), aimed  to compare the significant  
bilirubin   rebound after  phototherapy in two groups   of neonates  with  two levels of 
bilirubin  for discontinuation of phototherapy . In the first group phototherapy was 
discontinued when the serum bilirubin reaches 11mg/dl or the 40
th
 percentile of Bhutani‟s 
normogram. In the second  group,  phototherapy  was stopped    when the  total  serum  
bilirubin    level  drops  to  13mg/dl  or the 75
th
   percentile as per Bhutani‟s 
normogram.Serum bilirubin  was   measured  after   24 hrs  of  stopping   phototherapy. 
They defined  the   significant  rebound   when the bilirubin increase  more than  2mg/dl 
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or it reaches the 95
th
   percentile.   Their  study  included  115  neonate, of which  13   
neonates   developed  significant  rebound   after   stopping    phototherapy, 9  neonates  
in the first   group and  4  neonates   in the   second   group. But the   difference was not 
statistically   significant. They   concluded that   discontinuation   of phototherapy at a 
lower   serum  bilirubin   would not  result in   the   rebound  rise   in  bilirubin . Also in 
their study, they reported that   6 out of 13  neonates   with  risk   factors    developed   
significant    rebound    after    24 hours  of stopping phototherapy.  Hence   they 
suggested   a longer  period  of  follow  up after   stopping   phototherapy  if the infants  
had risk factor   for  significant    hyperbilirubinemia. 
 Soni et al(31), published a study from North India, the study aimed to determine 
the incidence and risk factors for the post phototherapy rebound hyperbilirubinemia.the 
study included neonates with gestational age more than 34 weeks of gestation and treated 
as per AAP guidelines. They measured serum bilirubin at around 24 hours and they 
defined significant rebound when the rise in serum bilirubin need re institution of 
phototherapy. They studied 501 neonates and reported the incidence of significant 
rebound bilirubinemia to be 12 %. They found the risk factors associated with the 
significant rebound include prematurity, ABO or Rh incompatibility, G6PD deficiency 
and the onset of jaundice less than 72 hours. Most of the findings were concurrent with 
that of Bansal et al study.  
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 Chang et al(32), in 2017 published a retrospective study which aimed to develop a 
prediction rule to estimate the probability of rebound hyperbilirubinemia following 
discontinuation of phototherapy. They suggested a prediction score which consist of three 
variable. In includes, gestational age < 38 weeks of gestation, age at initiation of 
phototherapy and the serum bilirubin level at which phototherapy was discontinued. The 
conclude that the chance of rebound hyperbilirubinemia can be quantified with these 
three variable. 
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METHODOLOGY 
Materials and methods: 
Study place: Neonatal intensive care unit, PSGIMS&R 
Study design: Open labelled randomized controlled trial.  
Study duration: From January 2018 to October 2018 
Study population: Newborn of gestational age ≥35 weeks with neonatal 
hyperbilirubinemia who meet the AAP criteria for phototherapy. 
 Inclusion criteria: 
1. Babies with gestationalage ≥35 weeks,  
2. Babies with birth weight >1800 grams,  
3. Babies requiring phototherapy for the first time,  
4. Babies with onset of jaundice ≤7 days. 
 Exclusion criteria:  
1. Babies planned for immediate exchange transfusion at the time of admission. 
Sample size: For calculation of sample size duration of phototherapy between two 
groups was considered from a pilot study by Barak et al with α error of 5% and power of 
80%. The estimated sample size is 99 in each group. Considering 20 % dropouts from the 
study, final sample size of 120 babies in each group was arrived. 
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Methodology: 
The study proposal was approved by Institutional Human ethics Committee and 
was prospectively registered in the Clinical Trial Registry of India (CTRI No: 
CTRI/2018/02/011740, Registered on 07/02/2018) 
 New born with gestational age ≥35 weeks with neonatal hyperbilirubinemia who 
meet the AAP criteria for phototherapy were contacted for the study. Babies with 
exclusion criteria were excluded from the study. After getting written informed consent, 
babies were recruited for the study.  
Randomization was done by variable block randomisation. Randomisation details 
were concealed in sequentially numbered, opaque, sealed envelope. Once the baby was 
recruited, envelope was opened and babies were assigned into either group A or group B 
as mentioned in the envelope.  
In group A, phototherapy was discontinued at 1.0-2.9 mg/dl below treatment 
threshold at which phototherapy was initiated. 
In group B, phototherapy was discontinued at ≥ 3mg/dl below the treatment 
threshold at which phototherapy was started. 
Data including birth weight, gestational age, gender, maternal blood group, history 
of jaundice in siblings, breast feeding, presence of scalp hematoma and excessive weight 
loss were collected in the case report form (CRF). 
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As per the unit protocol, at admission basic investigations were done. It includes 
Complete blood count, peripheral smear, Direct Coombs test, reticulocyte count and 
serum albumin. Additional investigation for septic screen and G6PD assay were done 
when clinically indicated.  
Babies were given phototherapy and serum bilirubin was monitored every 6 hours 
during phototherapy. Babies with serum bilirubin level approaching exchange transfusion 
threshold were monitored more frequently. 
Phototherapy was discontinued once serum bilirubin drops to 1.0-2.9mg/dl or 
≥3.0mg/dl below treatment threshold as per the group assigned. After stopping 
phototherapy, serum bilirubin was checked at 6 and 24 hours for rebound 
hyperbilirubinemia. 
If the serum bilirubin after stopping phototherapy increase to the age and risk 
specific cut-off as per American Academy of Paediatrics phototherapy charts, 
phototherapy was reinitiated. The second course of phototherapy was stopped when the 
total serum bilirubin level decreases to less than 13mg/dl as per our unit protocol.  
We defined significant rebound hyperbilirubinemia as an increase in the serum 
bilirubin to a level requiring second course of phototherapy. 
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Statistical methods: 
Number of babies who require re-initiation of phototherapy will be determined. 
Total duration of phototherapy including treatment after rebound hyperbilirubinemia and 
total duration of hospital stay will be calculated. Continuous variable will be compared 
using Student t test and categorical variable will be compared using chi square test. 
Significance is defined as a p value less than 0.05 or in case of Odds ratio determination a 
95% confidence interval that did not include the digit. 
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RESULTS 
We have recruited a total of 198 babies and by randomisation 99 babies were 
assigned to group A and 99 babies were assigned into group B. All these babies were 
treated as per the group assigned.  
In group A, 1 baby got discharged after stopping phototherapy and follow up 
bilirubin measurement could not be done. 15 babies were lost to follow up for second 
rebound bilirubin measurement. Hence the remaining 83 babies, who completed the 
study, were included for final analysis.   
In group B, 3 babies were withdrawn from the study during treatment and 1 baby 
initially had unconjugated hyperbilirubinemia and recruited for the study later while 
treatment developed conjugated hyperbilirubinemia, hence withdrawn from the study. 2 
babies got discharged after stopping phototherapy and follow up bilirubin measurement 
could not be done. 16 babies were lost to follow up for second rebound bilirubin 
measurement. Hence the remaining 77 babies, who completed the study, were included 
for final analysis.  
22 babies from group A, for whom phototherapy was planned to stop at a serum 
bilirubin level 1.0 to 2.9 mg/dl below the AAP treatment threshold, had their serum 
bilirubin level below 3.0 mg/dl while on phototherapy. 
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  Babies who meet the inclusion 
criteria and consented for study 
were included 
          Randomized   (n=198) 
 Allocated to Group A(n=99)                
 Received intervention-  99                      
 Did not received 
intervention-0 
 
 
Allocated to Group B                                    
 Received intervention- 95                    
 Did not received intervention- 
4  
(3- withdrawn from the study,                  
1- withdrawn due to 
conjugated 
hyperbilirubinemia) 
Lost to follow up- 16 
 1st Rebound bilirubin not 
available- 1 
 2nd Rebound bilirubin not 
available- 15 
Lost to follow up- 18 
 1st Rebound bilirubin not 
available- 2 
 2nd Rebound bilirubin not 
available- 16 
             Analysed (n=83)                  Analysed (n=77) 
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As we followed strict protocol for phototherapy discontinuation, we did intention 
to treat analysis, hence we included 83 babies in group A and 77 babies in group B for 
analysis.   
Baseline Characters: 
The baseline characters were depicted in Table 2.  
Table 2: Baseline characters of two groups of study population 
 Group A 
(n= 83) 
Group B 
(n= 77) 
P Value 
Birth Weight (grams) 2911.8 ± 428.9 2890.1 ± 442.7 0.754 
Gestational Age (weeks) 37.8 ±1.4 37.8 ± 1.2 0.462 
Male : Female ratio 1.3:1 0.6:1 0.012 
Exclusively Breastfed 71 (85%)  66 (85%) 0.578 
Extravasation 5 (6%) 3 (4%) 0.402 
ExcessiveWeight loss 20 (24%) 28 (36%) 0.064 
Hemolysis 4 (5%) 7 (9%) 0.226 
DCT positivity  4 (5%) 4 (5%) 0.598 
Septic screen positivity 5 (6%) 4 (5%) 0.406 
AAP Category 
    Low risk 
   Medium risk 
   High risk 
 
21 (25%) 
52 (63%) 
10 (12%) 
 
20 (26%) 
48 (62%) 
9 (12%) 
 
 
0.994 
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The baseline characters of two groups of our study participants were comparable 
except the sex ratio.  
The male: female ratio was 1.3:1 in group A and 0.6:1 in group B and the 
difference was statistically significant (p=0.012). 
Figure shows the gender distribution between two groups. In group A, there were 
47 male and 36 female babies. In group B, there were 29 male and 48 female babies. 
Figure 6: Gender distribution in two groups 
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Figure 7: The baseline characters of babies in two groups. 
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In both the groups 85% of babies were exclusively breastfed and was not 
statistically significant (p= 0.578).  
Scalp hematomas were present in 6% of babies in group A and 4% in group B and 
the difference was not statistically significant (p= 0.402).  
In group A 24 % of babies found to had excessive weight loss and in group B 36% 
of babies had excessive weight loss and the difference was not statistically significant (p= 
0.064).  
Evidence of hemolysis be peripheral smear and reticulocyte was positive in 5% of 
babies in group A and 9% of babies in group B and the difference was not statistically 
significant (p= 0.226).  
Direct Coombs test was found to be positive in 5% of babies in both the groups 
and the difference was not statistically significant (p= 0.598).  
Septic screen was found to be positive in 6% of babies in group A and 5% of 
babies in group B and the difference was not statistically significant (p= 0.406).  
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Distribution of babies among AAP risk category 
In group A we got 25% of babies with low risk, 63% with medium risk and 12% 
with high risk. In group B, 26% were belong to low risk, 63% were medium risk and 12% 
were high risk category. The distribution of babies on the basis of different AAP risk 
category was not statistically different between the two groups (p= 0.994) 
Figure 8: Distribution of babies among AAP risk category in two groups. 
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Outcomes: 
Table 3: The outcomes of two groups of the study 
 Group A 
( N= 83) 
Group B 
(N=77) 
P Value 
Age at initiation of 
phototherapy,(hours) 
73.5 ± 12.6 78.4 ± 20.3 0.067 
Age at stopping phototherapy, (hours) 88.5 ± 11.8 98.0 ± 20.7 0.000 
Time of 1
st
 rebound sample, (hours) 6.3 ± 0.6 6.3 ± 0.9 0.935 
Time of 2
nd
 rebound sample, (hours) 22.4 ± 9.1 22.3 ± 6.8 0.970 
Duration of phototherapy, hours 14.9 ± 5.8 19.5 ±8.6 0.000 
Length of hospital stay, hours  114.9 ± 25.3 116.7 ± 31.2 0.695 
Newborn requiring additional 
phototherapy, n 
2 (2.4%) 2 (2.6%) 0.661 
 
 The mean age at initiation of phototherapy was 73.5 hours (SD=12.6) in group A 
and 78.4 hours (SD= 20.3) in group B and the difference is not statistically significant 
(p= 0.067). 
 The mean age at stopping phototherapy was 88.5 hours (SD= 11.8) in group A and 
98 hours (SD= 20.7) in group B and the difference is statistically significant (p= 0.000). 
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 The mean time duration of first rebound bilirubin measurement after stopping 
phototherapy was 6.3 hours (SD=0.6) in group A and 6.3 hours (SD= 0.9) in group B and 
the difference is not statistically significant (p= 0.935). 
 The mean time duration of second rebound bilirubin measurement after stopping 
phototherapy was 22.4 hours (SD=9.1) in group A and 22.3 hours (SD= 6.8) in group B 
and the difference is not statistically significant (p= 0.970). 
 The mean duration of phototherapy was 14.9 hours (SD= 5.8) in group A and 19.5 
hours (SD= 8.6) in group B and the difference was statistically significant (p= 0.000) 
 The mean duration of hospital stay was 114.9 hours (SD= 25.3) in group A and 
116.7 (SD= 31.2) hours in group B and the difference was not statistically significant (p= 
0.695) 
 In group A 2 babies (2.4%) developed significant rebound hyperbilirubinemia and 
was given second course of phototherapy and in group B 2 babies (2.6%) developed 
significant rebound hyperbilirubinemia the difference is not statistically significant (p= 
0.661).   
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Figure 9: The percentage distribution of babies with significant rebound jaundice in 
two groups 
 
 
 We did the sub group analysis of babies based on the risk category they belong as 
per the AAP guidelines.  
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Low Risk Category 
Table 4:Outcomes of babies with low risk as per the AAP guidelines 
 Group A (n=21) Group B (n= 20) P value 
Age at initiation of 
phototherapy,(hours) 
73.6 ± 11.8 80.3 ± 13.5 0.102 
Age at stopping phototherapy, 
(hours) 
87.2 ± 11.8 95.2 ± 12.7 0.043 
Time of 1
st
 rebound sample, 
(hours) 
6.3 ± 0.6 6.5 ± 1.4 0.635 
Time of 2
nd
 rebound sample, 
(hours) 
23.7 ± 10.4 21.9 ± 6.2 0.527 
Duration of phototherapy, hours 13.5 ± 5.2 14.7 ± 5.0 0.448 
Length of hospital stay, hours  111.7 ± 16.6 119.4 ± 23.8 0.238 
Newborn requiring additional 
phototherapy, n 
0 0  
 
The mean age at initiation of phototherapy was 73.6 hours (SD=11.8) in group A 
and 80.3 hours (SD= 13.5) in group B and the difference was not statistically significant 
(p= 0.067). 
 The mean age at stopping phototherapy was 87.2 hours (SD= 11.8) in group A and 
95.2 hours (SD= 12.7) in group B and the difference was statistically significant (p= 
0.043). 
67 
 The mean time duration of first rebound bilirubin measurement after stopping 
phototherapy was 6.3 hours (SD=0.6) in group A and 6.5 hours (SD= 1.4) in group B and 
the difference was not statistically significant (p= 0.635). 
 The mean time duration of second rebound bilirubin measurement after stopping 
phototherapy was 23.7 hours (SD= 10.4) in group A and 21.9 hours (SD= 6.2) in group B 
and the difference was not statistically significant (p= 0.527). 
 The mean duration of phototherapy was 13.5 hours (SD= 5.2) in group A and 14.7 
hours (SD= 5.0) in group B and the difference was not statistically significant (p= 0.448) 
 
 The mean duration of hospital stay was 111.7 hours (SD= 16.6) in group A and 
119.4 (SD= 23.8) hours in group B and the difference was not statistically significant (p= 
0.238) 
 None of the babies in both group developed rebound hyperbilirubinemia. 
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Medium risk category: 
Table 5: Outcomes of babies withmedium risk as per AAP guidelines 
 
 
Group 
A(n=52) 
Group 
B(n=48) 
P Value 
Age at initiation of 
phototherapy,(hours) 
73.2 ± 13.7 78.8 ± 23.5 0.144 
Age at stopping phototherapy, (hours) 88.1 ± 12.2 100.3 ± 24.4 0.002 
Time of 1
st
 rebound sample, (hours) 6.3 ± 0.5 6.2 ±0.6 0.504 
Time of 2
nd
 rebound sample, (hours) 21.6 ± 9.2 22.6 ± 7.4 0.564 
Duration of phototherapy, hours 14.7 ± 5.7 21.4 ± 9.3 0.000 
Length of hospital stay, hours  113.5 ± 27.6 116.3 ± 36.3 0.665 
Newborn requiring additional 
phototherapy, n 
1 2 0.47 
 
The mean age at initiation of phototherapy was 73.2 hours (SD= 13.7) in group A 
and 78.8 hours (SD= 23.5) in group B and the difference was not statistically significant 
(p= 0.144). 
The mean age at stopping phototherapy was 88.1 hours (SD= 12.2) in group A and 
100.3 hours (SD= 24.4) in group B and the difference was statistically significant (p= 
0.000) 
69 
 The mean time duration of first rebound bilirubin measurement after stopping 
phototherapy was 6.3 hours (SD=0.5) in group A and 6.2 hours (SD= 0.6) in group B and 
the difference was not statistically significant (p= 0.504). 
 The mean time duration of second rebound bilirubin measurement after stopping 
phototherapy was 21.6 hours (SD= 9.2) in group A and 22.6 hours (SD= 7.4) in group B 
and the difference was not statistically significant (p= 0.564). 
 The mean duration of phototherapy was 14.7 hours (SD= 5.7) in group A and 21.4 
hours (SD= 9.3) in group B and the difference was statistically significant (p= 0.000) 
 The mean duration of hospital stay was 113.5 hours (SD= 27.6) in group A and 
116.3 (SD= 36.3) hours in group B and the difference was not statistically significant (p= 
0.665). 
 In group A 1 babies (1.9%) developed significant rebound hyperbilirubinemia and 
was given second course of phototherapy and in group B 2 babies (4.1%) developed 
significant rebound hyperbilirubinemia the difference was not statistically significant (p= 
0.47). 
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High Risk category 
Table 6: Outcomes of babies withHigh risk as per AAP guidelines 
 Group 
A(n=10) 
Group 
B(n=9) 
P 
Value 
Age at initiation of phototherapy,(hours) 74.7 ± 8.3 71.9 ± 13.3 0.583 
Age at stopping phototherapy, (hours) 92.8 ± 10.1 92.2 ± 10.1 0.903 
Time of 1
st
 rebound sample, (hours) 6.2 ± 0.4 6.3 ± 0.7 0.620 
Time of 2
nd
 rebound sample, (hours) 23.7 ± 5.0 21.9 ± 5.6 0.469 
Duration of phototherapy, hours 18.6 ± 6.4 20.3 ± 7.8 0.603 
Length of hospital stay, hours  129.1 ± 25.3 112.9 ± 10.9 0.094 
Newborn requiring additional phototherapy, n 1 0 0.526 
 
The mean age at initiation of phototherapy was 74.7 hours (SD= 8.3) in group A 
and 71.9 hours (SD= 13.3) in group B and the difference was not statistically significant 
(p= 0.583). 
The mean age at stopping phototherapy was 92.8 hours (SD= 10.1) in group A and 
92.2 hours (SD= 10.1) in group B and the difference was not statistically significant (p= 
0.903). 
 The mean time duration of first rebound bilirubin measurement after stopping 
phototherapy was 6.2 hours (SD=0.4) in group A and 6.3 hours (SD= 0.7) in group B and 
the difference was not statistically significant (p= 0.620). 
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 The mean time duration of second rebound bilirubin measurement after stopping 
phototherapy was 23.7 hours (SD= 5.0) in group A and 21.9 hours (SD= 5.6) in group B 
and the difference was not statistically significant (p= 0.469). 
 The mean duration of phototherapy was 18.6 hours (SD= 6.4) in group A and 20.3 
hours (SD= 7.8) in group B and the difference was statistically significant (p= 0.603) 
 The mean duration of hospital stay was 129.1 hours (SD= 25.3) in group A and 
112.9 (SD= 10.9) hours in group B and the difference was not statistically significant (p= 
0.094). 
 In group A 1 babies (10%) developed significant rebound hyperbilirubinemia and 
was given second course of phototherapy and in group B none developed significant 
rebound hyperbilirubinemia the difference is not statistically significant (p= 0.526). 
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DISCUSSION 
In our study, we found that the occurrence of significant rebound 
hyperbilirubinemia does not differ significantly between the two groups, when 
phototherapy was stopped at a serum bilirubin 1- 2.9 mg/dl and ≥3mg/dl below the level 
at which phototherapy was initiated.  
Authors of different studies used various cut-off of serum bilirubin level to stop 
phototherapy.  Tan(21), in his article, he suggested to stop phototherapy at a serum 
bilirubin level of 11mg/dl.  Lazar et al (20) in his study used a higher serum bilirubin 
level than suggested by Tan, to stop phototherapy. In their study they stopped 
phototherapy at mean serum bilirubin level of 13±0.7 mg/dl in term babies. For preterm 
babies they stopped phototherapy at a mean serum bilirubin level of 10.7 ± 1.2 mg/dl. 
They did not include babies with haemolytic conditions in their study.  
Barak et al, (4), in their pilot study compared the outcomes of two groups of 
neonatal hyperbilirubinemia when phototherapy was stopped at two targets below the 
AAP treatment threshold(2). They reported that the need for second course of 
phototherapy was not significantly different when phototherapy was stopped at 1mg/dl 
and 3 mg/dl below the AAP treatment threshold respectively. We from our study results 
agree the views of Barak et al.  
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The base line characters of our study participants were comparable in all the 
aspects except the sex ratio. In group A the male: female ratio was 1.3:1 and in group B it 
was 0.6:1. We could not achieve the final sample size of 240, that could be a possibility 
of the difference in sex ratio between two groups. Also we did not consider that sex of the 
baby would have an effect on the occurrence of significant rebound jaundice and affect 
the results of the study.  
We found that the duration of the phototherapy is significantly less when the 
phototherapy is discontinued when serum bilirubin falls 1 mg/dl below AAP cut-off. The 
mean duration of phototherapy was about 15 hours in 1mg/dl group and about 20 hours in 
3mg/dl group. This can reduce the cost for the treatment if phototherapy was stopped at a 
higher level without increasing the risk of rebound jaundice. 
Although our study showed that the duration of phototherapy is significantly less 
when phototherapy was stopped at a higher level, the mean duration of hospital stay was 
not significantly less. The mean duration of hospital stay differs by only 2 hours between 
the groups. This may be due the discharging policy of the unit. Most of our hospital 
discharges occur by afternoon of a day. Hence even if the baby gets ready for discharge 
after phototherapy by late night or morning, discharges usually occur along with mother 
by afternoon. Another observation which supports this fact is that the age at 
discontinuation of phototherapy, which is significantly less in the 1mg/dl. The mean age 
at discontinuation of phototherapy was 88 hours when it was stopped at 1mg/dl below 
cut-off and 98 hours when phototherapy was stopped at 3mg/dl below cut- off.  
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Out of four babies who had significant rebound hyperbilirubinemia, two babies 
were term with gestational age more than 38 weeks with features of hemolysis. Two 
babies were late preterm, of which one had additional risk of hemolysis. Age at initiation 
of phototherapy of all the four babies was less than 72 hours. These finding corresponds 
with that of previous studies which reported the risk factors of rebound jaundice. Kaplan 
et al in his study reported that rebound jaundice was more in babies with neonates <37 
weeks and in babies with onset of jaundice <72 hours. 
We did the sub group analysis depends on the risk category according to the AAP 
guidelines. It showed that in low risk babies, no baby had experienced a significant 
rebound hyperbilirubinemia requiring repeat course of phototherapy in both the groups 
studied. Previous studies also reported that the chance for rebound jaundice was less in 
the absence of risk factors. Our study also supports the reports of Kaplan et al reported 
that the risk of significant rebound was higher in babies with gestational age <37 weeks 
and with hemolytic disease. Hence for low risk babies without any risk factors the chance 
of rebound jaundice is less and phototherapy can be stopped at a higher bilirubin level 
safely. 
In babies with medium risk category, 1 baby from group A and 2 babies from 
group B had rebound hyperbilirubinemia requiring repeat course of phototherapy. But 
this difference is not statistically significant. The duration of phototherapy is significantly 
less in group A as observed in overall analysis. 
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In high risk category, 1 out of 10 babies from group A experienced rebound 
hyperbilirubinemia requiring repeat course of phototherapy.  None of the 9 babies from 
group B had significant rebound hyperbilirubinemia. This difference is also not 
statistically significant.  However, we got only 19 babies for analysis in this category and 
it constitute around 12 % of the study population. We included all the babies with 
neonatal jaundice hence we could not get equal distribution of cases between AAP risk 
category. We suggest that the high risk babies should be targeted separately and studied 
to ensure that stopping phototherapy at higher bilirubin level would not cause significant 
increase in rebound jaundice. 
The strength of our study was the study design, a randomised controlled trial; 
hence the chances of bias were less. Although we could not get the required sample size 
of 99 babies in each group, we have achieved 80 percent of the required sample size. We 
designed the protocol to stop phototherapy in two groups at a level, either 1mg/dl or 3 
mg/dl, below the AAP treatment threshold. This design is advantageous that the serum 
bilirubin level at which we stopped phototherapy was dynamic as that of the disease 
course. We got different cut off for stopping the phototherapy in each babies and it is 
related to their own treatment threshold.  
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LIMITATIONS 
The limitations of this study were that we could not achieve the final sample size 
calculated and this study is an open labelled trial. We don‟t think that the lack of blinding 
would result in bias as we have followed a strict protocol once the baby got recruited and 
deviations from protocol were not allowed.  
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CONCLUSION 
We suggest that in babies with neonatal jaundice, phototherapy can be stopped at a 
serum bilirubin level of 1mg/dl below the AAP treatment threshold at which 
phototherapy was initiated without any increased risk of rebound jaundice. We 
recommend that future studies should be targeted for high risk babies. 
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RBC          :  Red Blood Cells 
UGT1A1   : Uridine diphosphate- glucuronosyltransferase 1A1 
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0 0 2 2 0 0 2 15.5 16.2 72 14.5 13.5 84 6 13.5 62 15.1 0 0 0 14 0 0 0 0 12 122 1 1
1 0 2 2 0 0 3 12.0 13.2 54 9.0 7.5 95 6 6.9 NA NA 0 0 0 35 0 0 0 0 35 103 1 2
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1 0 2 2 0 0 2 13.0 13.0 48 10.0 9.4 64 6 9.2 14 9.9 0 0 0 16 0 0 0 0 16 93 1 2
1 0 2 2 0 0 2 14.0 15.2 52 13.0 11.5 60 6 11.5 NA NA 0 0 0 8 0 0 0 0 8 79 1 1
0 0 2 2 0 0 2 14.5 14.7 56 11.5 12.0 76 6 11.1 NA NA 0 0 0 20 0 0 0 0 20 95 1 2
0 0 2 2 0 0 2 14.5 17.0 68 13.5 13.8 88 6 12.2 NA NA 0 0 0 20 0 0 0 0 20 97 1 1
1 0 2 2 0 0 2 13.0 13.9 53 10.0 10.5 93 NA NA NA NA 0 0 0 40 0 0 0 0 40 93 2 2
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0 0 2 0 0 0 3 12.5 14.9 76 9.5 9.3 96 6 7.7 22 9.3 0 0 0 20 0 0 0 0 20 92 1 2
0 0 2 2 0 0 2 16.5 18.9 117 13.5 12.5 137 5 13.1 24 16.5 0 0 0 20 0 0 0 0 20.0 48.0 2 2
0 0 2 2 0 0 2 15.5 15.6 76 12.5 12.3 85 6 11.7 NA NA 0 0 0 9 0 0 0 0 9 98 1 2
0 0 2 2 0 0 1 15.0 15.3 47 14.0 13.4 60 6 12.6 NA NA 0 0 0 13 0 0 0 0 13 73 1 1
0 0 2 2 0 0 1 17.0 19.3 76 14.0 13.2 97 6 12.7 NA NA 0 0 0 24 0 0 0 0 24 120 1 2
0 0 2 2 0 0 3 13.0 16.0 70 10.0 8.9 98 7 8.9 NA NA 0 0 0 28 0 0 0 0 28.0 117.0 1 2
0 0 2 2 0 0 1 18.0 21.5 83 17.0 16.1 98 6 14.5 58 16.0 0 0 0 15 0 0 0 0 15 107 1 1
0 0 2 2 0 0 1 17.5 17.9 79 16.5 16.0 92 6 14.4 NA NA 0 0 0 13 0 0 0 0 13 101 1 1
0 0 2 2 0 0 2 15.5 17.1 82 14.5 11.4 96 6 11.2 NA NA 0 0 0 14 0 0 0 0 14 100 1 2
0 0 2 2 0 0 3 15.0 19.6 126 12.0 10.2 150 6 12.2 NA NA 0 0 0 24 0 0 0 0 24 173 1 2
0 0 2 2 0 0 1 17.0 17.1 76 14.0 12.8 94 5 12.5 30 15.4 0 0 0 18 0 0 0 0 18 145 1 2
1 0 2 2 0 0 2 15.0 15.1 75 12.0 10.2 90 6 9.7 NA NA 0 0 0 15 0 0 0 0 15.0 100.0 1 2
0 0 2 2 0 0 1 16.0 16.2 69 15.0 13.4 84 6 13.2 36 16.0 0 0 0 15 0 0 0 0 15 95 1 1
0 0 2 2 0 0 1 16.5 16.7 63 15.5 12.9 79 6 12.3 30 13.2 0 0 0 14 0 0 0 0 14 89 1 2
0 0 2 2 0 0 2 15.0 15.7 66 12.0 10.8 86 5 10.9 NA NA 0 0 0 20 0 0 0 0 20 100 1 2
0 0 2 2 0 0 2 15.0 15.5 70 12.0 12.4 NA N/A N/A NA NA 0 0 0 7 0 0 0 0 7 71 2 3
0 0 2 2 0 0 2 14.5 16.3 60 13.5 13.4 79 6 13.1 NA NA 0 0 0 19 0 0 0 0 19 75 1 1
0 0 2 2 0 0 2 15.0 16.9 75 14.0 12.9 83 7 11.0 NA NA 0 0 0 8 0 0 0 0 8 102 1 1
1 0 2 2 0 0 2 15.0 16.4 72 12.0 12.0 94 6 10.1 25 11.2 0 0 0 22 0 0 0 0 22 115 1 2
0 0 2 2 0 0 2 15.0 15.9 71 14.0 12.3 85 6 12.7 12 13.2 0 0 0 14 0 0 0 0 14 100 1 1
0 0 2 2 0 0 2 15.5 15.7 85 12.5 11.9 106 6 10.4 NA NA 0 0 0 21 0 0 0 0 21 114 1 2
0 0 2 2 0 0 2 14.3 14.4 63 11.3 11.2 83 6 11.4 52 14.6 0 0 0 20 0 0 0 0 20 92 1 2
1 0 2 2 0 0 2 15.5 17.7 77 14.5 14.4 96 7 13.3 26 14.3 0 0 0 19 0 0 0 0 19 124 1 1
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0 0 2 2 0 0 2 15.5 16.5 77 14.5 13.5 91 6 12.3 14 13.2 0 0 0 14 0 0 0 0 14 105 1 1
0 0 2 2 0 0 1 17.0 17.1 75 14.0 12.6 93 7 11.6 24 13.4 0 0 0 18 0 0 0 0 18 124 1 2
0 0 2 2 0 0 2 15.0 16.0 74 14.0 12.5 87 6 10.6 12 11.8 0 0 0 13 0 0 0 0 13 98 1 1
0 0 2 2 0 0 1 17.0 17.1 82 14.0 14.0 97 N/A N/A N/A N/A 0 0 0 20 0 0 0 0 20 98 2 2
1 0 2 2 0 0 3 12.0 13.0 72 9.0 8.4 87 6 9.7 28 9.3 0 0 0 15 0 0 0 0 15 120 1 2
0 0 2 2 0 0 1 19.5 20.5 96 18.5 16.8 113 7 14.9 28 16.2 0 0 0 17 0 0 0 0 17 148 1 1
0 0 2 2 0 0 2 15.5 18.7 82 14.5 13.3 97 6 12.5 10 12.5 0 0 0 15 0 0 0 0 15 105 1 1
0 0 2 2 0 0 2 15.0 17.5 68 14.0 13.6 80 6 12.6 12 11.5 0 0 0 12 0 0 0 0 12 95 1 1
0 0 2 2 0 0 2 13.0 22.6 50 10.0 9.8 98 6 13.5 21 16.7 0 0 0 48 1 28 0 0 76 192 1 2
0 0 2 2 0 0 1 16.5 19.5 69 13.5 13.5 90 6 11.6 NA NA 0 0 0 21 0 0 0 0 21 99 1 2
0 0 2 2 0 0 1 18.0 19.7 77 15.0 12.7 91 7 10.5 25 11.5 0 0 0 14 0 0 0 0 14 122 1 2
0 0 2 2 0 0 2 17.0 18.3 103 14.0 13.3 118 7 13.1 12 12.2 0 0 0 15 0 0 0 0 15 130 2 2
0 0 2 2 0 0 2 13.5 14.0 56 10.5 10.4 96 6 10.7 25 12.2 0 0 0 40 0 0 0 0 40 144 1 2
0 0 2 2 0 0 1 16.0 16.2 65 15.0 14.8 80 8 13.6 NA NA 0 0 0 15 0 0 0 0 15 108 1 1
0 0 2 2 0 0 2 15.0 17.3 70 14.0 12.9 85 6 11.9 12 15.9 0 0 0 15 0 0 0 0 15 112 1 1
0 0 2 2 0 0 2 15.0 16.0 63 14.0 12.5 78 6 10.6 12 11.8 0 0 0 13 0 0 0 0 13 98 1 1
0 0 2 2 0 0 2 14.5 14.7 63 11.5 10.5 84 6 9.5 15 11.2 0 0 0 21 0 0 0 0 21 107 1 2
0 0 2 2 0 0 1 17.0 17.9 68 16.0 15.8 77 6 14.7 25 14.1 0 0 0 9 0 0 0 0 9 109 1 1
0 1 2 0 0 0 3 15.0 15.5 126 12.0 NA 135 NA NA NA NA NA NA NA NA NA NA NA NA NA NA withdrawn 3
0 0 2 2 0 0 2 15.0 16.1 72 12.0 10.0 92 6 9.3 28 10.3 0 0 0 20 0 0 0 0 20 101 1 2
0 0 2 2 0 0 1 17.0 17.5 69 16.0 15.1 89 6 14.7 13 15.8 0 0 0 20 0 0 0 0 20 98 1 1
0 0 2 2 0 0 3 14.0 15.5 83 13.0 11.9 98 6 12.4 31 13.7 0 0 0 14 0 0 0 0 15 143 1 1
1 0 2 2 0 0 2 13.5 20.4 51 12.5 11.5 72 6 11.5 25 13.7 0 0 0 21 0 0 0 0 21 148 1 1
0 0 2 2 0 0 2 16.0 16.1 72 15.0 14.8 80 8 13.6 25 11.9 0 0 0 8 0 0 0 0 8 101 1 2
0 0 2 2 0 0 2 14.0 14.3 63 11.0 10.6 79 6 10.2 25 12.0 0 0 0 16 0 0 0 0 16 107 1 2
0 0 2 2 0 0 1 17.5 18.2 100 16.5 14.9 109 6 14.2 13 13.6 0 0 0 9 0 0 0 0 9 126 1 1
0 0 2 2 0 0 2 14.0 15.9 76 11.0 10.3 95 6 8.9 25 11.0 0 0 0 21 0 0 0 0 19 123 1 2
0 0 2 2 0 0 1 17.3 17.3 73 14.3 13.6 81 5 11.4 12 12.4 0 0 0 8 0 0 0 0 8 96 1 2
1 0 2 2 0 0 2 14.5 15.7 63 13.5 12.7 79 6 10.2 22 9.6 0 0 0 16 0 0 0 0 16 94 1 1
0 0 2 2 0 0 2 14.5 17.4 58 13.5 13.5 75 7 13.7 20 12.6 0 0 0 17 0 0 0 0 17 87 1 1
0 0 2 2 0 0 2 17.0 17.1 92 14.0 13.0 116 9 11.9 22 10.1 0 0 0 24 0 0 0 0 24 120 1 2
0 0 2 2 0 0 2 17.0 18.5 83 16.0 14.4 104 6 13.6 20 15.1 0 0 0 21 0 0 0 0 21 132 1 1
0 0 2 2 0 0 2 16.5 16.8 72 13.5 12.3 94 6 11.5 20 13.4 0 0 0 22 0 0 0 0 22 126 1 2
0 0 2 2 0 0 2 17.0 17.5 95 14.0 12.2 117 6 10.9 16 11.1 0 0 0 22 0 0 0 0 22 142 1 2
0 0 2 2 0 0 2 14.5 16.4 68 13.5 13.4 76 6 11.5 12 11.8 0 0 0 8 0 0 0 0 8 93 1 1
0 0 2 2 0 0 2 15.0 15.4 70 12.0 11.4 88 7 10.4 23 11.8 0 0 0 18 0 0 0 0 18 116 1 2
0 0 2 2 0 0 1 16.5 21.6 66 15.5 10.7 89 6 10.3 21 9.2 0 0 0 23 0 0 0 0 23 117 1 2
0 0 2 2 0 0 2 18.0 18.2 110 17.0 16.4 118 8 13.7 20 15.5 0 0 0 8 0 0 0 0 8 30 1 1
0 0 2 2 0 0 1 18.0 18.4 84 15.0 14.0 93 6 12.7 20 13.4 0 0 0 9 0 0 0 0 9 114 1 2
0 0 2 2 0 0 1 16.5 20.5 66 15.5 14.6 74 6 12.6 29 16.5 0 0 0 8 0 0 0 0 8 112 1 1
0 0 2 2 0 0 3 12.5 15.0 64 9.5 9.5 95 7 9.1 15 8.8 0 0 0 31 0 0 0 0 31 111 1 2
0 0 2 2 0 0 3 12.5 15.1 66 9.5 9.0 90 8 10.8 29 10.5 0 0 0 24 0 0 0 0 24 120 1 2
0 0 2 2 0 0 2 13.5 15.0 57 12.5 11.9 72 8 11.4 20 13.0 0 0 0 15 0 0 0 0 15 97 1 1
0 0 2 0 0 0 2 15.0 19.2 56 12.0 11.8 85 6 12.7 28 15.7 0 0 0 29 0 0 0 0 29 133 1 2
0 0 2 2 0 0 2 15.0 16.8 71 14.0 13.1 85 7 12.9 15 13.8 0 0 0 14 0 0 0 0 14 99 1 1
0 0 2 2 0 0 2 14.5 14.6 71 13.5 13.4 81 6 12.7 23 14.7 0 0 0 10 0 0 0 0 10 106 1 1
0 0 2 2 0 0 2 15.0 16.5 71 12.0 10.9 85 6 10.0 17 12.2 0 0 0 14 0 0 0 0 14 122 1 2
0 0 2 2 0 0 2 15.0 15.5 71 12.0 9.8 86 7 9.9 24 12.7 0 0 0 15 0 0 0 0 15 117 1 2
0 0 2 2 0 0 1 17.5 18.9 76 14.5 14.0 99 6 13.2 23 15.8 0 0 0 23 0 0 0 0 23 151 1 2
0 0 2 1 0 0 2 14.0 14.3 64 13.0 12.3 78 6 11.2 10 11.0 0 0 0 14 0 0 0 0 14 91 1 1
0 0 2 2 0 0 3 13.0 14.1 72 12.0 11.3 86 6 10.9 NA NA 0 0 0 14 0 0 0 0 14 94 1 1
0 0 2 2 0 0 2 15.0 16.0 76 14.0 13.1 91 6 11.6 12 11.1 0 0 0 15 0 0 0 0 15 104 1 1
0 0 2 2 0 0 2 15.0 15.9 73 14.0 13.5 82 6 13.0 14 14.5 0 0 0 9 0 0 0 0 9 101 1 1
0 0 2 2 0 0 1 15.0 16.3 68 12.0 11.6 88 6 10.8 29 10.6 0 0 0 20 0 0 0 0 20 119 1 2
0 0 2 2 0 0 1 16.5 17.7 66 13.5 12.2 86 N/A N/A N/A N/A 0 0 0 20 0 0 0 0 20 90 2 2
0 0 2 0 0 0 2 14.5 14.5 71 11.5 10.9 86 7 9.1 12 9.7 0 0 0 15 0 0 0 0 15 100 1 2
0 0 2 0 0 0 2 14.0 15.3 57 11.0 9.9 90 6 10.8 12 11.8 0 0 0 33 0 0 0 0 33 106 1 2
0 0 2 2 0 0 2 15.2 15.9 72 12.2 11.9 87 6 9.8 12 11.0 0 0 0 15 0 0 0 0 15 99 1 2
0 0 2 2 0 0 2 15.0 16.2 75 14.0 12.7 88 6 11.2 NA NA 0 0 0 13 0 0 0 0 13 99 1 1
0 0 2 0 0 0 1 17.0 18.9 68 16.0 14.3 81 6 14.4 29 15.4 0 0 0 13 0 0 0 0 13 140 1 1
0 0 2 2 0 0 2 16.5 16.5 90 15.5 13.3 99 6 11.4 13 10.3 0 0 0 9 0 0 0 0 9 120 1 2
0 0 2 2 0 0 2 15.2 17.8 77 14.2 12.7 97 6 12.1 18 13.5 0 0 0 20 0 0 0 0 20 121 1 1
0 0 2 2 0 0 2 16.0 16.4 86 15.0 13.8 94 7 13.0 23 14.7 0 0 0 7 0 0 0 0 8 131 1 1
0 0 2 2 0 0 1 17.5 20.4 85 14.5 13.0 104 6 11.7 22 13.4 0 0 0 19 0 0 0 0 19 128 1 2
0 0 2 2 0 0 2 15.2 15.9 74 12.2 11.7 88 6 9.8 12 10.6 0 0 0 14 0 0 0 0 14 102 1 2
0 0 2 0 0 0 2 14.5 18.3 64 11.5 11.3 110 6 11.9 32 9.6 0 0 0 46 0 0 0 0 46 116 1 2
0 0 2 2 0 0 2 15.0 17.4 74 14.0 12.6 89 6 12.4 32 13.4 0 0 0 15 0 0 0 0 15 125 1 1
0 0 2 2 0 0 1 15.5 20.6 82 12.5 11.8 110 6 11.3 NA NA 0 0 0 28 0 0 0 0 28 43 1 2
0 0 2 2 0 0 3 13.0 16.4 75 12.0 10.6 105 6 10.5 18 11.5 0 0 0 30 0 0 0 0 30 124 1 1
0 0 2 2 0 0 2 15.0 15.0 76 12.0 10.5 98 6 11.1 24 12.7 0 0 0 22 0 0 0 0 22 125 1 2
0 0 2 2 0 0 3 14.0 15.8 88 13.0 12.8 110 6 12.0 24 13.3 0 0 0 22 0 0 0 0 22 139 1 1
0 0 2 2 0 0 1 17.5 18.4 81 14.5 12.8 97 7 10.8 29 14.4 0 0 0 16 0 0 0 0 16 107 1 2
0 0 2 2 0 0 2 14.5 14.5 64 13.5 13.4 77 6 13.1 20 10.2 0 0 0 13 0 0 0 0 13 85 1 1
0 0 2 2 0 0 2 17.5 17.5 102 14.5 13.9 111 6 11.0 32 12.7 0 0 0 9 0 0 0 0 9 149 1 2
1 0 2 2 0 0 2 13.0 18.3 49 12.0 10.9 76 NA NA NA NA 0 0 0 27 0 0 0 0 27 94 2 1
0 0 2 2 0 0 1 19.5 21.5 93 18.5 16.9 102 6 14.7 24 16.1 0 0 0 9 0 0 0 0 9 139 1 1
0 0 2 2 0 0 1 19.5 20.7 100 16.5 16.3 115 6 12.2 25 12.9 0 0 0 15 0 0 0 0 15 139 1 2
0 0 2 0 1 0 2 15.2 18.5 73 14.2 14.1 86 7 12.5 32 11.0 0 0 0 13 0 0 0 0 13 97 1 1
0 0 2 2 0 0 2 18.0 19.5 119 17.0 16.1 135 6 14.8 12 14.9 0 0 0 16 0 0 0 0 16 144 1 1
0 0 2 2 0 0 1 17.0 17.1 93 14.0 13.4 114 6 12.8 22 13.6 0 0 0 15 0 0 0 0 15 152 1 2
0 0 2 2 0 0 2 18.0 18.7 149 15.0 13.3 163 7 13.1 22 13.8 0 0 0 14 0 0 0 0 14 40 1 2
0 0 2 2 0 0 2 14.2 14.4 62 13.2 9.1 76 6 8.7 26 10.3 0 0 0 14 0 0 0 0 14 110 1 2
0 0 2 2 0 0 2 15.5 15.5 76 12.5 11.9 96 6 11.5 24 11.7 0 0 0 20 0 0 0 0 20 124 1 2
0 0 2 2 0 0 2 14.0 14.6 53 11.0 11.2 NA N/A NA NA NA 0 0 0 19 0 0 0 0 19 84 2 3
0 0 2 2 0 0 1 17.0 21.4 74 16.0 15.7 101 6 16.5 18 16.8 0 0 0 27 0 0 0 0 27 121 1 1
0 0 2 2 0 0 3 13.0 14.6 69 12.0 11.3 83 6 11.8 27 13.6 0 0 0 14 1 18 0 0 32 190 1 1
0 0 2 2 0 0 1 16.5 16.5 64 13.5 11.6 78 6 10.2 24 9.7 0 0 0 14 0 0 0 0 14 106 1 2
0 0 2 2 0 0 2 14.5 14.5 67 11.5 9.6 81 6 7.0 NA NA 0 0 0 14 0 0 0 0 14 90 1 2
1 0 2 2 0 0 2 14.5 18.1 66 13.5 11.2 87 6 10.0 24 11.2 0 0 0 21 0 0 0 0 21 111 1 2
0 0 2 2 0 0 2 16.0 17.5 84 13.0 13.0 104 6 12.8 24 13.1 0 0 0 20 0 0 0 0 20 133 1 2
0 0 2 1 0 0 3 14.0 14.1 97 11.0 10.6 106 6 8.4 24 9.8 0 0 0 9 0 0 0 0 9 122 1 2
0 0 2 2 0 0 2 15.0 16.1 71 14.0 12.0 85 7 12.8 27 16.4 0 0 0 14 0 0 0 0 14 143 1 2
0 0 2 2 0 0 1 16.0 16.8 69 15.0 13.4 78 6 13.8 15 14.4 0 0 0 9 0 0 0 0 9 97 1 1
0 0 2 1 0 0 2 16.5 16.5 88 13.5 10.7 101 7 9.8 12 10.7 0 0 0 13 0 0 0 0 13 114 1 2
0 0 2 2 0 0 1 16.0 16.4 63 15.0 14.8 77 6 15.8 18 17.9 0 0 0 14 0 0 0 0 14 111 1 1
0 0 2 2 0 0 1 18.0 19.6 114 17.0 16.7 123 6 12.5 24 11.7 0 0 0 9 0 0 0 0 9 135 1 2
0 0 2 0 0 0 2 14.0 15.4 58 13.0 13.0 93 6 11.6 16 13.5 0 0 0 35 1 24 0 0 59 244 1 1
0 0 2 2 0 0 1 15.5 17.3 77 12.5 11.0 90 6 10.9 24 11.1 0 0 0 14 0 0 0 0 14 118 1 2
0 0 2 2 0 0 2 15.0 17.2 70 14.0 13.2 84 7 12.8 31 16.2 0 0 0 14 0 0 0 0 14 95 1 1
0 0 2 2 0 0 2 13.4 1.4 58 10.4 9.7 86 6 10.1 18 12.3 0 0 0 28 0 0 0 0 28 126 1 2
0 0 2 2 0 0 2 18.0 20.7 94 15.0 13.9 108 7 11.9 25 11.7 0 0 0 14 0 0 0 0 14 48 1 2
0 0 2 2 0 0 1 18.7 18.7 86 17.7 15.5 94 6 13.6 24 15.1 0 0 0 8 0 0 0 0 8 118 1 2
0 0 2 2 0 0 2 14.0 16.2 62 13.0 11.8 77 7 10.9 22 12.3 0 0 0 15 0 0 0 0 15 106 1 1
0 0 2 2 0 0 1 18.0 20.0 76 17.0 13.5 90 7 12.7 28 15.1 0 0 0 14 0 0 0 0 14 124 1 2
0 0 2 2 0 0 2 16.5 16.9 70 13.5 12.7 84 6 13.5 26 17.7 0 0 0 14 1 22 0 0 36 167 1 2
0 0 2 2 0 0 2 15.0 18.5 77 12.0 11.5 92 6 11.1 NA NA 0 0 0 15 0 0 0 0 15 102 1 2
0 0 2 2 0 0 2 16.5 17.3 85 15.5 14.9 94 7 11.6 36 13.8 0 0 0 9 0 0 0 0 9 110 1 1
1 0 2 2 0 0 3 13.0 15.7 73 12.0 9.8 87 6 9.9 NA NA 0 0 0 14 0 0 0 0 14 97 1 2
0 0 2 2 0 0 1 17.0 18.5 71 14.0 14.0 81 6 13.0 10 15.6 0 0 0 10 0 0 0 0 10 122 1 2
0 0 2 2 0 0 3 13.5 13.5 85 10.5 10.1 101 6 9.8 19 10.7 0 0 0 16 0 0 0 0 16 121 1 2
0 0 2 2 0 0 2 13.0 15.6 53 12.0 11.8 79 6 11.7 19 11.6 0 0 0 26 0 0 0 0 26 102 1 1
0 0 2 2 0 0 2 14.5 16.0 70 11.5 9.2 91 6 9.9 24 10.4 0 0 0 21 0 0 0 0 21 120 1 2
0 0 2 2 0 0 1 17.0 17.5 73 16.0 15.2 81 6 12.7 22 12.4 0 0 0 8 0 0 0 0 8 98 1 1
0 0 2 1 0 0 2 15.0 15.2 79 14.0 13.6 87 6 11.5 25 9.9 0 0 0 8 0 0 0 0 8 126 1 1
0 0 2 0 0 0 3 13.5 14.8 73 12.5 10.4 89 7 10.6 24 11.0 0 0 0 16 0 0 0 0 16 118 1 2
0 0 2 0 0 0 3 12.5 13.9 64 9.5 9.4 97 6 9.3 12 9.7 0 0 0 33 0 0 0 0 33 110 1 2
1 0 2 2 0 0 2 14.2 14.6 61 11.2 10.7 94 6 10.8 13 9.3 0 0 0 33 0 0 0 0 33 107 1 2
0 0 2 1 0 0 2 17.5 17.8 74 14.5 11.8 89 6 10.6 26 12.3 0 0 0 15 0 0 0 0 15 132 1 2
0 0 2 2 0 0 2 14.5 15.8 71 13.5 12.6 97 6 10.4 18 10.9 0 0 0 30 0 0 0 0 30 121 1 2
0 0 2 2 0 0 2 14.5 15.0 64 11.5 10.3 81 6 9.2 24 10.4 0 0 0 17 0 0 0 0 17 107 1 2
0 0 2 2 0 0 3 13.5 13.8 85 10.6 10.1 100 6 10.5 20 12.8 0 0 0 11 0 0 0 0 11 127 1 2
0 0 2 2 0 0 2 15.0 17.1 72 12.0 10.9 84 6 9.4 23 9.1 0 0 0 22 0 0 0 0 22 121 1 2
0 0 2 1 0 0 2 15.0 19.1 65 12.0 11.5 87 6 10.5 NA NA 0 0 0 22 0 0 0 0 22 97 1 2
0 0 2 2 0 0 1 17.5 21.2 73 16.5 13.5 87 6 14.8 12 13.8 0 0 0 14 0 0 0 0 14 102 1 2
0 0 2 2 0 0 2 15.5 15.6 79 14.5 13.8 88 6 12.4 16 12.9 0 0 0 9 0 0 0 0 9 104 1 1
0 0 2 0 0 0 2 15.5 16.4 77 12.5 12.1 92 6 10.9 24 11.2 0 0 0 15 0 0 0 0 15 123 1 2
0 0 2 2 0 0 1 18.0 18.7 86 15.0 14.8 95 6 14.6 16 14.7 0 0 0 9 0 0 0 0 9 112 1 2
0 0 2 1 0 0 2 17.5 17.9 62 14.5 11.8 88 7 10.9 26 12.8 0 0 0 15 0 0 0 0 15 132 1 2
0 0 2 1 0 0 2 16.5 16.8 86 15.5 14.8 95 6 15.8 32 16.6 0 0 0 9 0 0 0 0 9 144 1 1
0 0 2 2 0 0 2 13.0 15.3 54 12.0 11.1 74 6 10.0 23 9.5 0 0 0 20 0 0 0 0 20 100 1 1
0 0 2 2 0 0 2 17.5 17.6 129 14.5 12.3 144 6 10.8 24 12.1 0 0 0 15 0 0 0 0 15 42 1 2
0 0 2 2 0 0 1 17.5 18.3 77 14.5 14.2 85 7 13.5 15 13.8 0 0 0 8 0 0 0 0 8 42 1 2
0 0 2 2 0 0 2 15.0 15.6 68 14.0 13.7 83 6 12.1 25 12.4 0 0 0 15 0 0 0 0 15 114 1 1
0 0 2 2 0 0 3 13.0 14.2 72 10.0 8.7 87 6 9.2 24 10.5 0 0 0 15 0 0 0 0 15 121 1 2
0 0 2 2 0 0 2 12.4 14.2 47 11.4 11.3 73 6 14.0 24 12.9 0 0 0 26 0 0 0 0 26 110 1 1
0 0 2 2 0 0 2 18.0 19.4 115 15.0 14.5 150 6 13.8 26 15.5 0 0 0 20 0 0 0 0 43 165 1 2
0 0 2 2 0 0 2 15.0 16.0 69 14.0 13.3 79 6 10.5 16 10.5 0 0 0 10 0 0 0 0 10 98 1 1
0 0 2 2 0 0 2 16.5 17.0 83 13.5 13.5 97 6 13.2 30 14.7 0 0 0 14 0 0 0 0 14 25 1 2
0 0 2 2 0 0 3 13.0 14.9 70 12.0 9.7 85 7 8.8 26 8.7 0 0 0 15 0 0 0 0 15 123 1 2
0 0 2 2 0 0 2 16.0 17.8 80 15.0 14.2 100 6 12.9 20 12.6 0 0 0 20 0 0 0 0 20 108 1 1
0 0 2 2 0 0 1 18.0 18.6 78 15.0 14.6 93 6 14.4 30 15.2 0 0 0 15 0 0 0 0 15 128 1 2
0 0 2 2 0 0 3 13.5 14.9 65 12.5 12.1 80 6 11.8 27 11.8 0 0 0 15 0 0 0 0 15 94 1 1
0 0 2 2 0 0 1 15.0 16.6 53 12.0 11.2 79 12 11.8 24 12.2 0 0 0 26 0 0 0 0 26 104 1 2
0 0 2 2 0 0 3 12.0 15.8 51 9.0 8.9 71 6 10.1 24 12.1 0 0 0 20 0 0 0 0 20 99 1 2
0 0 2 1 0 0 2 15.0 15.1 147 12.0 10.8 196 6 11.4 36 10.8 1 0 0 49 0 0 0 0 49 232 1 2
0 0 2 2 0 0 2 15.0 15.3 77 12.0 11.0 93 6 9.2 21 11.6 0 0 0 16 0 0 0 0 16 146 1 2
0 0 2 2 0 0 2 16.5 17.3 85 15.5 14.7 93 6 15.1 38 14.6 0 0 0 8 0 0 0 0 8 132 1 1
0 0 2 2 0 0 3 12.5 13.9 64 11.5 11.2 85 6 9.8 26 12.9 0 0 0 21 0 0 0 0 21 112 1 1
0 0 2 2 0 0 2 18.0 20.2 124 15.0 13.1 138 6 11.6 25 12.0 0 0 0 14 0 0 0 0 14 146 1 2
0 0 2 1 0 0 2 13.5 14.8 56 10.5 10.4 80 6 10.2 22 13.2 0 0 0 24 0 0 0 0 24 105 1 2
0 0 2 0 0 0 2 15.0 17.5 64 12.0 12.0 87 6 12.9 30 15.0 0 0 0 23 0 0 0 0 23 138 1 2
0 0 2 2 0 0 1 15.5 16.5 55 14.5 14.2 71 8 13.9 26 14.7 0 0 0 16 0 0 0 0 16 104 1 1
0 0 2 2 0 0 2 15.0 15.7 70 14.0 13.6 78 7 11.2 17 12.0 0 0 0 8 0 0 0 0 8 97 1 1
0 0 2 2 0 0 1 16.0 19.5 62 15.0 13.1 75 8 13.4 13 13.9 0 0 0 13 0 0 0 0 13 91 1 1
0 0 2 2 0 0 2 16.5 21.4 94 15.5 13.4 107 6 13.8 23 14.7 0 0 0 13 0 0 0 0 13 144 1 2
MASTER CHART
